University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

12-2014

Enhancement of Chronically-induced Breast Carcinogenesis by
Combined Environmental and Dietary Carcinogens and
Suppression by Dietary Agents
Lenora A. Pluchino
University of Tennessee - Knoxville, lpluchin@vols.utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss
Part of the Life Sciences Commons

Recommended Citation
Pluchino, Lenora A., "Enhancement of Chronically-induced Breast Carcinogenesis by Combined
Environmental and Dietary Carcinogens and Suppression by Dietary Agents. " PhD diss., University of
Tennessee, 2014.
https://trace.tennessee.edu/utk_graddiss/3200

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Lenora A. Pluchino entitled "Enhancement of
Chronically-induced Breast Carcinogenesis by Combined Environmental and Dietary
Carcinogens and Suppression by Dietary Agents." I have examined the final electronic copy of
this dissertation for form and content and recommend that it be accepted in partial fulfillment
of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences.
Hwa-Chain R. Wang, Major Professor
We have read this dissertation and recommend its acceptance:
Ranjan Ganguly, Brynn Voy, Hong Guo
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

Enhancement of Chronically-induced Breast Carcinogenesis by Combined
Environmental and Dietary Carcinogens and Suppression by Dietary Agents

A Dissertation Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville

Lenora A. Pluchino
December 2014

Copyright © 2014 by Lenora A. Pluchino
All rights reserved.

ii

DEDICATION

This dissertation is dedicated to David Antoine, the greatest friend anyone ever had. You
will forever be in my heart. May you rest in peace and take solace in knowing that someday
we will be together again.

iii

ACKNOWLEDGEMENTS
I express my gratitude and sincere regards to my mentor Dr. Hwa-Chain Robert Wang for
giving me an opportunity to work and learn in his laboratory and for his guidance, supervision
and encouragement during my training. His goal-oriented research ethic and constant advice has
instilled scientific culture in my life and motivated me to pursue my goals. I would like to also
extend my sincere gratitude to members of my advisory committee, Drs. Ranjan Ganguly, Brynn
Voy, and Hong Guo for their time, advice and guidance.
I express my thanks to all past and present members of the laboratory for providing a
helpful and stimulating research environment. Specifically, I would like to thank Drs. Shilpa
Sood, Shambhunath Choudhary and Kusum Rathore for all the help and time they have given me
during my formative years in the lab.
I thank the Program for Excellence and Equity in Research (PEER) and the Graduate
School of Genome Science and Technology (GST) for the opportunity and financial support
needed to conduct my research. I would like to especially thank Drs. Sekeenia Haynes, Cynthia
Peterson and Albrect von Arnim for enabling me to pursue graduate study under the PEER
fellowship and the GST program and for their unwavering support during my years of training. I
would like to acknowledge my colleges, Ms. Dianne Trent for her technical assistance with flow
cytometry experiments and Ms. Misty Bailey for her textual editing of the manuscripts.
I express my deepest gratitude to my mother Nadine and brother John who have always
supported me and motivated me to come this far. Special thanks to Diamond, Bella, Slinky, Nala,
Eddie, Bruno and Rosa for providing me with your unconditional love and comic relief during all
my years of hard work away from home.
-Lenora A. Pluchino
iv

ABSTRACT
Most breast cancers occur sporadically due to long-term exposure to low-dose
carcinogens present in our environment and diet. American lifestyles involve frequent exposures
to smoke, polluted air, and high temperature-cooked meats comprising multiple carcinogens,
such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[α[alpha]]pyrene
(B[α[alpha]]P), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). To investigate
whether these carcinogens may act together to enhance breast cell carcinogenesis, we used our
chronically-induced breast cell carcinogenesis model wherein we repeatedly expose noncancerous human breast epithelial MCF10A cells to physiologically-achievable doses of
carcinogens to progressively induce cellular acquisition of cancer-associated properties including
reduced dependence on growth factors, anchorage-independent growth, increased cell
proliferation, migration and invasion and enriched stem-like cell population. These properties are
then used as targets to identify dietary agents capable of blocking carcinogen-induced breast cell
carcinogenesis.
In the first part of this research (Chapter 2), we demonstrated that cumulative exposures
to combined NNK and B[α[alpha]]P (NB) holistically enhanced progression of breast cell
carcinogenesis chronically-induced by PhIP. Cells co-exposed to NB and PhIP (NBP) acquired
higher degrees of cancer-associated properties including enhanced induction of the epithelial-tomesenchymal transition program and enriched stem-like cell populations compared to cells
sequentially exposed to NB followed by PhIP (NB/P). Using these cancer-associated properties
as targets, we demonstrated that combined green tea catechins (GTCs) were more effective than
individual catechins in suppression of cellular carcinogenesis chronically induced by NBP.
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Studies in Chapter 3 revealed that reactive oxygen species (ROS) and ERK pathway
activation were transiently induced by NBP during each exposure. Cross-talk between reinforced
ROS elevation and the ERK pathway played an essential role in increased DNA oxidation and
damage which contributed to enhanced initiation of cellular carcinogenesis and led to enhanced
acquisition of cancer-associated properties. Using NBP-induced transient changes and cancerassociated properties as targets, we revealed that physiologically-achievable levels of combined
dietary ergosterol and mimosine were highly effective in blocking NBP-induced transient
endpoints, including ROS-mediated DNA oxidation, which accounted for their ability to
suppress progression of NBP-induced cellular carcinogenesis. Thus, combined dietary
components such as GTCs, ergosterol and mimosine should be considered for affordable
prevention of sporadic breast cancer associated with long-term exposure to environmental and
dietary carcinogens.
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CHAPTER 1

Background and Overview
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Introduction
Given the ubiquitous nature of tobacco smoke, carbon exhaust, and cooked meat in
modern societies, it is important to holistically examine the role of carcinogens, such as NNK,
B[α]P, and PhIP, in induction of breast cell carcinogenesis to reveal associated mechanisms and
targeted endpoints for intervention. The objectives of this study were to (1) elucidate the ability,
and associated mechanisms, of environmental carcinogens NNK and B[α]P to enhance breast
cell carcinogenesis induced by dietary carcinogen PhIP and (2) demonstrate the ability, and
associated mechanisms, of combined dietary agents to more effectively suppress breast cell
carcinogenesis induced by combined NNK, B[α]P, and PhIP.

Breast Cancer
Cancer refers to a group of diseases characterized by abnormal and uncontrollable cell
growth which ultimately leads to the formation of a mass or tumor. Breast cancer can begin in
the breast tissue, which consists of fatty, connective and lymphatic tissues, the glands for milk
production, called lobules, or the ducts that connect these lobules to the nipple [1]. Cancers that
originate in the duct are known as ductal carcinomas while those originating in the lobules are
called lobular carcinomas [2]. Breast cancer is the most common type of cancer and secondleading cause of cancer related death among women in North America and Europe [1,2]. The
National Cancer Institute projects there will be 232,670 new cases of invasive breast cancer in
American women in 2014 resulting in approximately 40,000 deaths [2]. On a global scale, breast
cancer represents 23% of all cancers diagnosed in women [3]. While rates of breast cancer vary
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around the world, developed countries typically have rates that are much higher than developing
countries [4] (Figure 1.1).

Stages of Breast Cancer
Staging is the process of assessing how advanced a cancer has progressed and where it is
located in the body. The purpose of staging is to ascertain the extent and severity of the disease
in an individual [5]. Staging of breast cancer is important for determining prognosis and
treatment options. As described by the National Cancer Institute [6], the four stages of breast
cancer are as follows (Figure 1.2):
Stage 0: (carcinoma in situ)
This is a pre-cancerous stage of which three types exist:
a) Ductal carcinoma in situ (DCIS): a non-invasive condition in which abnormal cells
are found in the lining of a breast duct. These cells have not spread outside of the duct
to other tissues of the breast.
b) Lobular carcinoma in situ (LCIS): a non-invasive condition in which abnormal cells
are found in the lobules of the breast. These cells have not spread outside of the
lobule to other tissues of the breast; however, having LCIS increases the risk of
developing invasive breast cancer.
Stage I:
During Stage I, cancer has formed in either breast. Stage one tumors are typically 2 centimeters
or less in diameter and have not spread outside of the breast tissue.
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Stage II:
Stage II describes invasive breast cancer in which one of the following is true:
a) The tumor is 2 centimeters or less in diameter, but has spread to the lymph nodes
under the arm.
b) The tumor is 2-5 centimeters in diameter and may or may not have spread to the
lymph nodes under the arm.
c) No tumor is found in the breast, but breast cancer cells are found in the lymph nodes
under the arm.
d) The tumor is more than 5 centimeters in diameter, but hasn’t spread to any lymph
nodes.
Stage III:
Stage III cancers are invasive but have not yet spread to distant sites. This stage is further divided
into three substages:
a) Stage IIIA: Breast tumor is more than 5 centimeters in diameter and has spread to one
to three lymph nodes under the arm; or tumor can be any size and has spread to
multiple lymph nodes under the arm.
b) Stage IIIB: A tumor of any size that has spread to skin or muscle tissues near the
breast and may have spread to lymph nodes under the arm or within the breast itself.
c) Stage IIIC: A tumor of any size that has spread to 10 or more lymph nodes under the
arm, lymph nodes within the breast, and to lymph nodes around the collarbone and
neck.
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Stage IV:
Stage IV cancers are metastatic and have spread beyond the breast and the adjacent lymph nodes
to distant organs of the body such as the lungs, liver, bone or brain.

Classification of Breast Cancer
Breast cancer is a group of diseases which encompasses various subtypes defined by
distinct morphological characteristics and clinical outcomes. According to the World Health
Organization, the most common type of breast cancer is invasive ductal carcinoma (IDC) [7].
IDC, which represents 8 out of 10 invasive breast cancers, starts in the milk duct and then
spreads into the fatty tissue of the breast [7]. From here, it may metastatize to other organs of the
body through the bloodstream or lymphatic system. The next most common type of breast cancer
is invasive lobular carcinoma (ILC) which arises from the milk-producing gland and also can
metastasize throughout the body [7].
Newer technologies such as immunohistochemistry, cytogenetics and cDNA microarray
analysis have been employed to further classify invasive breast cancers into four distinct
molecular subtypes based on genetic factors, hormone receptor status and HER2/neu status [8].
As seen in Figure 1.3, these subtypes are named Luminal A, Luminal B, Triple negative/basallike, and HER2 type [8]:
a) Luminal A: Luminal tumors occur in the inner lining of the mammary duct and
account for most breast cancers. Luminal A tumor cells are estrogen receptor-positive
(ER+) and/or progesterone receptor-positive (PR+) and human epidermal growth
factor receptor-negative (HER2/neu-). These tumors are typically low-grade (grade 1
or 2) and are slow-growing and well-differentiated. Mutations in the tumor suppressor
5

gene p53, which are correlated with poor prognosis, occur in less than 15% of luminal
A tumors. These tumors have the best prognosis of all four subtypes of breast cancer
with high survival and low recurrence rates.
b) Luminal B: These tumors also occur in the inner lining of the mammary duct.
Luminal B tumor cells are ER+ and/or PR+, and HER2/neu+ and/or highly positive for
Ki67, a marker for tumor cell proliferation. Compared to luminal A tumors, luminal B
tumors have a poorer prognosis due to higher grade tumors (grade 3) which are
larger, fast-growing and poorly-differentiated, invasion of cancer cells into the lymph
nodes, and p53 mutations in about 30% of all tumors. Luminal B tumors are also
more commonly diagnosed in women at a younger age. However, women with
luminal B tumors still have considerably high survival rates, although not as high as
women with luminal A tumors.
c) Triple negative/basal-like: Triple negative tumor cells are ER-, PR-, and HER2/neu-.
Most triple negative tumors are classified as basal-like because the tumor cells
resemble cells of the outer (basal) lining of the mammary duct. Triple negative
tumors account for 15-20% of all breast cancers and are often aggressive, fast
growing and have poor prognosis. Most contain p53 mutations and mutations in the
BRCA1 gene. Since triple negative tumors do not express any hormone receptors,
they do not respond to traditional hormone-based chemotherapies and are therefore
more difficult to treat. Triple negative breast cancer is more common in younger
women and women of African-American decent and is more likely to recur than any
other subtype of breast cancer.
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d) HER2 type: HER2 type tumors are usually HER2+ (although they can be HER2-),
ER-, and PR-. They account for 10-15% of all breast cancers and have a fairly poor
prognosis due to high grade tumors, invasion of cancer cells into the lymph nodes,
and p53 mutations in about 75% of all tumors. They recur often, have a tendency to
metastasize early, and occur more commonly in younger women than luminal A or B
tumors.

Risk Factors for Breast Cancer
A risk factor is any environmental or genetic factor that increases a person’s chance of
getting a disease. Since cancer represents a diverse group of diseases, different cancers therefore
have different risk factors. Figure 1.4 summarizes the known risk factors for breast cancer as
stated by the Breast Cancer Organization [9]. Being a woman is the biggest risk factor for
developing breast cancer as men account for less than 1% of all new breast cancer cases. After
gender, age is the most significant risk factor with about two-thirds of invasive breast cancers
occurring in women 55 or older. Family history also contributes to breast cancer risk. Women
that have a first-degree relative (mother, daughter, sister) that has been diagnosed with breast
cancer have double the average risk of developing the disease.
Approximately 5-10% of breast cancers are thought to be hereditary [9]. Most cases of
hereditary breast cancer are associated with mutations in the BRCA1/2 tumor suppressor genes
[9, 10]. The BRCA1/2 proteins form a complex that participates in a DNA damage response
pathway that initiates homologous recombination and double-strand break repairs [11]. Loss of
functional BRCA1/2 results in an inability to repair DNA leading to mutations in other genes. As
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a result, women who have inherited inactivating mutations in either the BRCA1 or BRCA2 genes
have a significantly increased risk of developing breast and/or ovarian cancer [10].
One’s personal history of breast or other cancers can influence the risk of developing new
breast cancer. If you’ve previously had breast cancer, you are 3-4 times more likely to develop
new cancer in a different part of the breast and this risk is in addition to the risk of the original
cancer coming back (recurrence) [9]. Even being diagnosed with certain benign breast conditions
can increase the risk of breast cancer development. Also, radiation exposure to the chest or face
to treat another type of cancer can increase the risk for developing breast cancer later in life [9].
Other biological factors known to be associated with increased risk of breast cancer are
early first menses (age 12 or younger), late occurring menopause (after age 55), and not having
had a full-term pregnancy by age 30 [9]. Race and ethnicity also play a role in assessing breast
cancer susceptibility. While Caucasian women are slightly more likely to develop breast cancer
than African-American, Hispanic or Asian women, African-American women are more likely to
develop aggressive, early-onset, and advanced-stage breast cancer [9].
Overweight and obese women are at a higher risk for developing breast cancer than
women who maintain a normal weight, especially after menopause [9]. Being overweight can
also increase the risk of recurrence in women who have already had the disease. Other lifestyle
factors that contribute to increased risk of breast cancer include lack of exercise, smoking,
alcohol consumption and using hormone replacement therapy after menopause [9].
Studies have shown that only 5-10% of breast cancers have a genetic basis [12]. Most
breast cancers are non-genetic and are caused by environmental factors. Subsequently, it is
important to understand the role of these environmental factors in breast cancer development.
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Environmental Carcinogens
Carcinogens are any naturally-occurring or synthetic substance that can cause cancer.
Humans are exposed to a variety of chemicals from the environment each day. Chemicals in air,
water, soil and food as well as occupational exposure and lifestyle factors all contribute to the
complex exposure situation most people experience in their daily lives [13]. Approximately 90%
of breast cancers are considered non-hereditary or ‘sporadic’ [12]. These sporadically occurring
cancers often result from chronic exposure of human tissues to low-doses of environmental
carcinogens. Thus, it is imperative to study and understand the factors that contribute to sporadic
breast cancers in order to devise an effective strategy for preventing and controlling these
diseases. Figure 1.5 shows the types of environmental factors that have the potential to cause
non-hereditary cancer. The American Cancer Society [14] has classified these factors as related
to lifestyle (tobacco, alcohol, diet, inactivity, being overweight), naturally-occurring substances
(ultraviolet radiation, infectious agents, radon), chemicals in the home or workplace (auto
exhaust, second-hand smoke, asbestos), medical treatments (hormone-replacement therapy,
immune-suppressing treatments) and others.

Related to Lifestyle
Factors related to lifestyle are often not cancer-causing agents themselves, but are risk
factors associated with the genesis of cancer since they ultimately result in exposure to higher
levels of carcinogens [15]. It is well recognized that tobacco use, alcohol consumption, diet
imbalance, obesity and sedentary lifestyle can contribute to cancer especially in affluent
countries [15].
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Tobacco Smoking
Tobacco smoking is a significant risk factor for the initiation and progression of human
carcinogenesis in multiple organs [16]. Tobacco smoke contains thousands of carcinogenic
compounds including mutagens such as polycyclic aromatic hydrocarbons and nitrosamines [16].
Smoking is a risk factor for many types of cancer, most notably lung cancer, but also cancers of
the digestive tract, bladder, liver, esophagus, kidney, stomach, pancreas, breast and cervix [17].
The link between smoking and breast cancer is controversial; however, recent studies indicate that
exposure to tobacco smoke can increase breast cancer risk, especially in post-menopausal women [18-20].

Since many of these cancers are associated with poor prognosis, tobacco use is by far the most
widespread link between exposure to carcinogens and cancer-related death [16].

Alcohol Consumption
Alcohol is not by itself mutagenic to DNA and therefore is not a true carcinogen. Rather,
alcohol acts mainly as a co-carcinogen by influencing the metabolic activation of other
carcinogens [16]. Epidemiological data supports the classification of alcohol as a human
carcinogen [21] and other studies have shown that alcohol can potentiate the carcinogenic
potential associated with other risk factors such as smoking [22].

Diet
Several studies have indicated an association between a diet rich in calories and fat and
low in fiber and the development of several cancers (prostate, breast and colon) in developed
countries [23,24]. A major class of dietary carcinogens is heterocyclic amines which are present
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in high quantities in well-done meats [25]. These compounds are highly mutagenic and
epidemiological studies have indicated that consumption of well-done meat may play a role in
the development of breast and other cancers [26].

Obesity and Sedentary Lifestyle
Obesity and inactivity are touted as important risk factors contributing to the
development of a myriad of diseases, including many cancers [27]. Obesity was also shown to
increase cancer-related mortality in a cohort of US adults [28]. Rates of breast and other cancers
are higher in developed countries where a substantial portion of the population is obese or
overweight due to poor diet and physical inactivity [29]. According to the American Institute for
Cancer Research, body fat alone is responsible for over 100,000 cancers in the US annually
including cancers of the endometrium, esophagus, pancreas, kidney, gallbladder, breast and
colon [30].

Naturally-Occurring Substances

Ultraviolet Rays
Ultraviolet rays and ionizing radiation have the potential to cause DNA damage and
contribute to cancer development, particularly melanoma [31]. In fact, UV irradiation is one of
the most relevant risk factors for the development of skin cancer [32]. UV radiation is considered
a complete carcinogen since it is mutagenic and acts as both a tumor initiator and tumor
promoter [32]. Partially due to increased recreational sunbathing and use of tanning beds, UV11

induced tumors are rapidly rising in incidence not only in the US but also in Europe and
Australia [33].

Infectious Agents
Studies have indicated that 18-20% of cancers are linked to infectious agents such as
viruses, bacteria and parasites [34]. Some infectious agents cause inflammation which may
enhance tumorigenicity [34] and retroviruses can cause incorporation or disruption of protooncogenes [35]. The bacterium H. pylori has been shown to have a causal relationship to gastric
cancer [36] and human papilloma virus (HPV) has been linked to cervical cancer [37]. New
studies are consistently detecting numerous emerging pathogens capable of causing cancer in
humans [38].

Radon
Radon, a colorless, odorless, radioactive gas, is produced from the radioactive decay of
uranium or thorium and is among the most widely studied environmental carcinogens [39]. It is
found in soil, rock and water and can even get into indoor and outdoor air [40]. Levels are
especially high in basements where radon leaks in through gaps in the floor or walls [40].
Exposure to high levels of radon has been linked to lung cancer and is the second leading cause
of lung cancer incidence after smoking [39]. In the US alone, radon is responsible for
approximately 22,000 lung cancer-related deaths annually [39].
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Chemicals in the Home or Workplace
A large number of chemical carcinogens are recognized by the National Institute of
Environmental Health Sciences as “known” or “reasonably anticipated” to cause cancer. The list
includes benzene, diesel exhaust, tobacco smoke, pesticides, substances used for some industrial
processes such as cadmium used to manufacture batteries and compounds found in some
consumer goods such as diethanolamine (DEA) which is present in many shampoos and lotions
[41]. Many other environmental substances are currently under investigation to determine their
carcinogenic potential. Some important chemical carcinogens are discussed in detail below.

Diesel Exhaust
Diesel exhaust is produced from the combustion of diesel fuel given off by vehicles that
run on diesel engines such as cars, trucks, farm equipment and construction vehicles [42]. It is a
major component of air pollution as it contains many toxic contaminants such as sulfur oxides
and particulate matter [42] and is classified as an environmental carcinogen [41]. Exposure to
diesel exhaust is associated with increased risk of lung cancer with those experiencing high
occupational exposure being the most susceptible [43].

Second-hand Smoke
Also referred to as passive smoke, second-hand smoke contains over 4,000 chemical
compounds, over 60 of which are either known or suspected to cause human cancer [44].
Second-hand smoke is especially unhealthy in enclosed areas such as homes, cars, offices and
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restaurants. Exposure to second-hand smoke has been shown to be linked with increased
incidence of lung cancer [45] and breast cancer, especially in post-menopausal women [18-20].

Asbestos
Asbestos is a commercial term used to refer to a group of naturally-occurring fibrous
silicate minerals once widely used in the construction industry to insulate homes and buildings
[46]. Still found in older buildings, exposure to asbestos is known to increase the risk of lung and
laryngeal cancers, malignant mesothelioma (a rare cancer of the outer protective lining of the
lung and inner chest cavity) as well as non-cancerous respiratory diseases such as asbestosis,
especially in those who experience high occupational exposure [47]. The total number of deaths
in the US due to asbestos-related lung cancer, mesothelioma and asbestosis resulting from
workplace exposure is estimated to be over 200,000 in 2014 [48].

Medical Treatments
Hormone replacement therapy (HRT) is used extensively to treat osteoporosis and relieve
symptoms of menopause. However, its widespread long-term use for prevention of
cardiovascular disease or cognitive decline has been disputed by several epidemiological studies
that have linked such therapies to a variety of cancers [49-53]. The risk of breast cancer varies
with the type of HRT. The most significant risk is associated with opposed estrogen (combined
estrogen and progesterone) given in oral form, which further increases breast cancer risk the
longer it is used [50]. HRT has also been shown to increase the risk of ovarian [51], colorectal
[52] and brain cancers [53].
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Immunosuppressive medications are necessary to prevent graft or organ rejection in
patients who have recently received transplants. As a result of suppressing the immune system,
organ transplant recipients are at an increased risk for developing infections and certain types of
cancers [54-55]. The mechanisms by which immunosuppressive medications promote tumor
growth is not currently known, however several studies have associated the type, duration and
intensity of immunosuppressive treatments with the development of skin cancer [56] and
lymphoma [57].

Others
There are many other environmental factors that play a role in cancer development. Airborne particulate materials from vehicles and industrial processes that cause cancer include
powdered cobalt and nickel and crystalline silica [58]. Other carcinogens we encounter in our
everyday lives include antiperspirants, talcum powder, hair dyes and some cosmetics [59], but
exposure to these chemicals needs to be at occupational levels to cause a significant carcinogenic
effect [60].
This study concerns the activity of the environmental carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[α]pyrene (B[α]P) and the dietary carcinogen
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) to induce and enhance breast cell
carcinogenesis. These carcinogens are discussed in detail in following sections.
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4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
The role of tobacco carcinogens in the development of human breast cancer is still up for
debate, however increasing evidence suggests a link between active and passive smoking and
high incidence of sporadic breast cancer, especially in post-menopausal women [16, 18-20, 6164]. Therefore, it is important to investigate the impact of long-term cumulative exposure to
tobacco carcinogens on chronic transformation of breast epithelial cells in order to elucidate the
roles of these carcinogens in the progressive development of breast cancer.
Nicotine-derived nitrosamine ketone (NNK), or 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (Figure 1.6A), is a tobacco-specific nitrosamine produced from the nitrosation of
nicotine that occurs during the curing and processing of tobacco [65]. NNK is a pro-carcinogen
that requires metabolic activation by the cytochrome P450 enzyme CYP2A6 [66]. NNK is
considered one of the most potent carcinogens in tobacco products and is known to induce a high
incidence of lung cancers in humans [67-68] and laboratory animals [69-70]. Active metabolites
of NNK frequently form DNA adducts which result in activating point mutations of protooncogenes [71, 72]. NNK also acts as a potent agonist for β-adrenergic and α7-nicotinic
acetylcholine receptors and stimulates arachidonic acid-dependent and ERK-dependent
mitogenic pathways associated with these receptors [73-76].
The association between smoking and breast cancer is still controversial. Some studies
have indicated that smoking has no influence on breast cancer incidence [77] while others have
shown a correlation between the two [78]. Recent cohort studies in Canada [18] and the United
States [20] have determined that active smoking and exposure to second-hand smoke increases
breast cancer risk, especially in post-menopausal women [19]. However, despite increasing
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evidence, NNK is still considered a non-mammary carcinogen. Therefore, the role of tobacco
carcinogens on breast cell carcinogenesis needs to be further investigated.

Benzo[α]pyrene (B[α]P)
Benzo[α]pyrene (B[α]P) (Figure 1.6B) is a five-ring aromatic polycyclic hydrocarbon
generated from the incomplete combustion of organic materials [16]. B[α]P is known to be
involved in human cancers of the lungs, skin and bladder and is classified as a Group I
carcinogen by the IARC since its metabolites are highly mutagenic and carcinogenic [17].
Metabolic activation of B[α]P is mediated by CYP1B1 [77]. B[α]P is found in coal tar, charcoal
barbequed and wood-fire grilled foods, automobile exhaust (especially from diesel engines) and
tobacco smoke [16, 42, 44]. Cooked meats have been shown to contain B[α]P [78] up to 5.5 ng/g
in fried chicken [79] and 62.6 ng/g in well-done barbecued beef [80]. Therefore, B[α]P is
considered both an environmental and dietary carcinogen.
B[α]P intercalates into DNA by covalently bonding to nucleophilic guanine bases at the
N2 position causing distortion of the double-helix. Perturbation of DNA structure disrupts
normal DNA copying and induces mutations ultimately leading to cancer development following
exposure [81]. B[α]P has been identified as a mammary carcinogen in rodents [63, 82, 83], and
some studies have indicated that B[α]P may contribute to human breast cancer development
because its metabolites form strong DNA adducts that cause DNA lesions [81, 83, 84]. However,
the correlation between B[α]P exposure and breast cancer occurrence in women is modest [8486]. Therefore, B[α]P may be considered a weak mammary carcinogen in humans, but may play
an important role in enhancement of precancerous carcinogenesis of human breast cells caused
by other carcinogens.
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2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP)
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) (Figure 1.6C) is a
heterocyclic amine (HCA) generated during the cooking of meats from the breakdown of
creatine, amino acids and sugars [87]. PhIP is the most abundant HCA found in cooked meats
and, as shown in Table 1.1, its abundance increases with cooking time and temperature with
particularly high amounts found in well-done meats [26]. PhIP is a pro-carcinogen that requires
metabolic activation through CYP1A2-mediated N-oxidation or O-acetylation mediated by
polymorphic N-acetyltransferase 2 (NAT2) [26]. PhIP possesses high mutagenic activity
compared to other HCAs because its structure (N-methyl group in the 1-position) makes it more
available for interaction with the enzyme active sites of CYP1A2 and NAT2 resulting in higher
rates of oxidation or acetylation, respectively [88]. The mutagenic potency of the resulting PhIP
metabolites is 100-fold higher than those of related HCAs due to increased stability of the
reactive intermediates and the resulting DNA adducts [88].
PhIP is known to induce mammary cancer in rodents [25, 89-91] and its link to human
cancers of the breast, colorectum and prostate is well established [26, 92-99]. Epidemiological
studies have indicated a strong correlation between consumption of well-done meats and
increased risk of breast cancer [26, 95, 96-98]. Risk of breast cancer development from PhIP
exposure is particularly high in post-menopausal women and women possessing a NAT2
polymorphism exhibiting high O-acetyltransferase activity [94, 95, 97, 99]. A study on PhIPDNA adducts in normal breast tissue of women with newly diagnosed breast cancer indicated
that the extent of adduct formation was positively correlated with well-done meat consumption
and NAT2 genotype [99].
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Human consumption of PhIP at microgram levels results in systemic exposure at pico to
low nanomolar levels [25] and detection of PhIP as high as 59 pg/mL in the milk of healthy
women indicates that ductal mammary epithelial cells are directly exposed to PhIP [100]. PhIP is
known to induce activation mutations in the H-Ras proto-oncogene [25, 91] and exposure to low
nanomolar doses of PhIP increased proliferation and activated the MAP kinase pathway in noncancerous immortalized human breast epithelial MCF10A cells [101]. This indicates that PhIP
can stimulate the activation of oncogenic signaling pathways at levels close to human exposure
[101].
We are all exposed to multiple mutagenic agents, such as the ones described above, in
our environment and diet each day. Since most breast cancers occur as a result of long-term
carcinogen exposure, it is important to examine how multiple carcinogens act together to induce
breast cell carcinogenesis. Additionally, further studies are needed to investigate how tobacco
carcinogen NNK and weak human mammary carcinogen B[α]P can contribute to precancerous
breast cell carcinogenesis.

Hallmarks of Cancer
The hallmarks of cancer consist of six biological capabilities acquired by cells during
carcinogenic transformation (Figure 1.7) [102]. As normal cells become neoplastic, they
successively acquire these hallmark characteristics enabling them to become tumorigenic and
metastatic. These properties include sustaining proliferative signaling, evading growth
suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis and
activating invasion and metastasis [102].
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Cancer cells can acquire the capacity to sustain proliferative signaling in a number of
ways. They may over-express cell surface growth factor receptors, exhibit deregulation of
growth factor signaling pathways, participate in paracrine proliferative signaling with normal
cells in the stromal environment or participate in autocrine proliferative signaling in which
cancer cells produce their own growth factor ligands [102]. Constitutive activation of
proliferative signaling pathways often results in growth factor independence since there is no
longer a need to stimulate these pathways by ligand-mediated receptor activation [102].
Enhancement of proliferative signaling may also result from defects in negative feedback
mechanisms meant to attenuate signaling, such as those mediated by PTEN or mTOR [103].
To ensure continued growth, cancer cells must evade programs that negatively regulate
proliferation, often through the action of tumor suppressors such as p53 or retinoblastoma protein
(pRb). Anti-growth signals block proliferation by inducing cells to enter either a temporary
quiescent state or a terminally differentiated post-mitotic state. During the G1 phase transition of
the cell cycle, cells are actively monitoring their surrounding environment for external signals
that will ultimately determine whether they will proliferate or enter into a quiescent or postmitotic state [102-103]. These signaling circuits can be disrupted in various ways in different
types of tumors. In many cancers, mutations eliminate expression of p53 and pRb tumor
suppressors, which play central roles in governing cell fate. Loss of pRB results in deregulated
proliferation and loss of p53 desensitizes cells to cell cycle checkpoints [104]. Some tumor cells
lose responsiveness to anti-proliferative signals due to down-regulated, mutated or disrupted
receptors. Additionally, tumor cells can turn off expression of integrins and other cell adhesion
molecules that send anti-proliferative signals [102-103].
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Apoptosis serves as a natural barrier to cancer development. During the course of
tumorigenesis, cancer cells experience a variety of apoptosis-inducing stresses including
hyperactive signaling by oncoproteins and DNA damage from hyperproliferation. The ability of
tumor cells to evade the apoptotic program ultimately leads to high-grade malignancy and
resistance to therapeutics [103]. The most common mechanism for avoiding apoptosis is through
loss of the p53 tumor suppressor. In normal cells, p53 induces apoptosis in response to
substantial DNA breaks and chromosomal abnormalities. However, p53-mediated DNA damage
sensing machinery is often impaired in cancer which eliminates this critical component from the
apoptosis-inducing circuitry [104]. Alternatively, tumor cells may evade apoptosis by increasing
expression of anti-apoptotic regulators, such as Bcl-2, or decreasing expression of proapoptotic
factors, such as Bax and Bim. Tumor cells may also increase production of survival signals, such
as insulin growth factor 1/2 (Igf1/2), to circumvent activation of apoptotic machinery [103].
Cancer cells require unlimited replicative potential in order to form tumors. Normal cells
are only able to pass through a limited number of division cycles before cells enter senescence,
and ultimately crisis, which culminates in cell death. Cells that have avoided senescence and
survive crisis are said to be immortalized and exhibit the capacity for unlimited replication.
Telomeres protecting the ends of chromosomes are centrally involved in unlimited replicative
potential. Telomeres usually shorten during each successive cell cycle leading to a loss in their
protective functions, triggering entrance into crisis. Telomerase, a DNA polymerase that adds
telomere repeat segments to the ends of chromosomal DNA, is over-expressed in immortalized
cells, including cancer cells. Over-expression of telomerase is associated with resistance to
senescence and crisis-associated cell death allowing cells to replicate indefinitely [103].
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During tumor progression, an “angiogenic switch” is almost always activated to induce
the growth of tumor-associated neovasculature which provides tumor cells with nutrients and
oxygen while allowing them to get rid of carbon dioxide and metabolic wastes. The best known
angiogenic inducers and inhibitors are vascular endothelial growth factor-A (VEGF-A) and
thrombospondin-1 (TSP-1), respectively, and regulation of angiogenesis depends on
counterbalance between the two. Expression of VEGF-A and its associated receptors can be upregulated in tumor cells by oncogene signaling downstream of Ras or Myc and by hypoxia which
often results from the high metabolic rates of cancer cells. Once angiogenesis is activated, other
proangiogenic factors, such as members of the fibroblast growth factor (FGF) family, are
chronically up-regulated to sustain tumor angiogenesis. A variety of other cell types have been
implicated in tumor angiogenesis, such as many bone-marrow derived cells of the innate immune
system including macrophages, neutrophils, mast cells and myeloid progenitors. These cells can
infiltrate tumors where they help trip the usually dormant angiogenic switch [103].
Progression of epithelial-derived carcinomas to higher pathological grades is
characterized by local invasion and metastasis. In order to accomplish this, tumor cells must alter
their attachment to other cells and to the extracellular matrix (ECM). As a result, expression of
genes involved in cell-cell or cell-ECM adhesion, such as E-cadherin, are often down-regulated
in carcinoma cells. Loss of E-cadherin or other adhesion molecules is known to potentiate
invasive and metastatic phenotypes. Conversely, adhesion molecules associated with cell
migration during embryogenesis and inflammation, such as N-cadherin, are often up-regulated. It
has become clear that a normally inactive developmental regulatory program called the
epithelial-to-mesencymal (EMT) transition program is involved in conferring cancer cells with
invasive capabilities. The EMT program can become aberrantly activated in transformed
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epithelial cells enabling them to acquire increased motility, invasiveness and dissemination
[103]. The EMT program and its role in cancer will be discussed in further detail below.
Since characterization of these six hallmarks of cancer in 2000 [102], several enabling
characteristics and emerging hallmarks have been identified (Figure 1.8) [103]. Acquisition of
the established hallmarks is made possible by two enabling characteristics, genomic instability
and chronic inflammation. First, the development of genomic instability in cancer cells generates
random gene mutations and chromosomal rearrangements which result in genetic changes that
induce or enhance hallmark capabilities. In fact, the acquisition of most hallmark characteristics
depends largely on genomic alterations in neoplastic cells. Besides mutations, epigenetic
mechanisms such as DNA methylation or histone modifications can also contribute to cellular
transformation. Essential to the orchestration of tumorigenesis is a breakdown in one or more
components of the genomic maintenance machinery, such as p53, via inactivating mutation or
epigenetic repression [103].
The second enabling characteristic is the inflammatory state of premalignant and
malignant lesions driven by immune cells. Most tumors are densely infiltrated with cells of the
innate and adaptive immune system that mimic inflammatory conditions in normal tissues.
Ironically, this immune response meant to eradicate tumors from the body’s tissues often has the
paradoxical effect of enhancing tumorigenesis. Inflammation can contribute to acquisition of
hallmark capabilities by ensuring a steady supply of bioactive molecules, such as growth factors,
proangiogenic factors and extracellular matrix-modifying enzymes, to the tumor
microenvironment. Additionally, inflammatory cells can also release molecules, such as reactive
oxygen species, that are actively mutagenic to tumor cells [103].
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Two attributes of cancer cells have recently been recognized as being functionally
important for cancer development and therefore may be considered as emerging hallmarks. The
first is major reprogramming of cellular energy metabolism to support constant cell growth and
proliferation. Non-cancerous cells usually rely on mitochondrial oxidative phosphorylation to
produced ATP for cellular processes, initiating glycolysis only under anaerobic conditions.
However, cancer cells can reprogram their energy production to fuel high glycolytic rates even
when oxygen is present. This is known as the Warburg effect. Initially proposed as the
underlying cause of cancer, it is now recognized to be a result of carcinogenic development.
Since glycolysis is an inefficient method of ATP production, cancer cells must make up for this
by increasing glucose uptake. Given this inefficiency, the benefit of this metabolic
reprogramming to cancer cells is still unclear [103].
The second emerging hallmark of cancer cells is the ability to evade immune destruction.
Constant immune surveillance is responsible for recognizing and eradicating that vast majority of
cancer cells, so any tumors that do form must have managed to escape detection by the immune
system. As mechanisms of immunoevasion, tumor cells may release high levels of immunosuppressive factors, such as TGF-β, or recruit inflammatory cells that are actively immunosuppressive, such as regulatory T cells. In epidemiological studies, significant increases in
certain types of cancers have been observed in immunocompromised individuals and high levels
of killer lymphocytes is associated with better prognosis in colon and ovarian cancers [103].

Precancerous Model of Cancer Progression
Most breast cancers occur sporadically, often as a result from chronic exposure to lowdoses of carcinogens present in the environment and diet. It is important to study the agents that
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contribute to sporadic breast cancers in order understand the mechanisms behind development of
these diseases and to devise effective strategies for prevention. To address this need, we have
developed a cellular model (Figure 1.9) that mimics chronic human breast cell carcinogenesis by
repeatedly exposing non-cancerous human breast epithelial cells to low physiologicallyachievable pico to nanomolar concentrations of environmental and dietary carcinogens, such as
NNK, B[α]P and PhIP, to imitate the carcinogen exposure encountered by people in their daily
lives. Metabolites of NNK can be detected at picomolar concentrations in the body fluids of
tobacco users [105] and metabolites of B[α]P can be detected at picomolar concentrations in
human fat and liver [106]. Human consumption of PhIP at microgram levels results in systemic
exposure at low nanomolar levels [25]. This model is used to reveal the potency of carcinogens
to induce chronic carcinogenesis of breast cells by measuring progressive cellular acquisition of
identifiable cancer-associated properties. These cancer-associated properties are then used as
targeted endpoints to identify dietary agents that are capable of reducing cellular acquisition of
these properties and suppressing carcinogenesis. Using this model, we repeatedly exposed
immortalized, non-cancerous human breast epithelial MCF10A cells to NNK, B[α]P and/or
PhIP, at pico or nanomolar concentrations, mimicking long-term exposure of breast tissues to the
low but ever-present levels of carcinogens present in the environment and diet. A single
exposure to these carcinogens induced transient biochemical, molecular and cellular changes
which contributed to progressive acquisition of cancer-associated properties after cumulative
exposures [107-115]. Importantly, our model highlights the relevance of using precancerous
stages as targets for cancer prevention in contrast to a therapeutic approach used to treat
malignancies.
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Detection of Cancer Progression
Reduced Dependence on Growth Factors
A lack of growth factors causes normal cells to undergo cell-cycle arrest and apoptosis;
however, transformed cells acquire a reduced dependence on growth factors (RDGF) to increase
survivability [108-115]. The constitutive activation of proliferative signaling pathways
downstream of growth factor receptors commonly seen in cancer cells eliminates the need for
ligand-mediated activation of these receptors. This often results in cellular acquisition of growth
factor independence conferring cancer cells with the ability to grow and proliferate without
stimulation from external growth signals [102].

Anchorage-Independent Growth
Anchorage of cells to the ECM is necessary for cellular survival in a multicell
environment. Normal cells that fail to stay attached to the ECM undergo a programmed cell
death response termed anoikis [116]. Anchorage-independent growth (AIG) aberrantly acquired
to promote cell survivability can contribute to malignant transformation. Cellular acquisition of
AIG is associated with phenotypic changes, such as the loss of contact inhibition and the ability
to colonize in soft agar, and is correlated with increased tumorigenicity and invasiveness in
several cell types [102, 116].
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Wound Healing
Cancerous cells acquire increased motility compared to their normal counterpart cells
[117]. When cell monolayers are scratched or “wounded” in culture, cells at the wound margin
respond to the disruption in cell-cell contacts by increasing their production of growth and other
stimulatory factors to heal the wounded area by a combination of increased proliferation and
motility [118,119]. Cancerous cells must acquire increased motility in order to migrate and
invade surrounding tissues. In many cases, activation of the EMT program enables cancerous
epithelial cells to acquire mesenchymal-like migratory capabilities [103]. Alternatively, some
cancer cells may acquire the ability to migrate in an ameboid-like manner similar to leukocytes
[117]. Increased cell motility in cancerous cells is closely related to the hallmark characteristics
of cell migration and invasion discussed below.

Migration and Invasion
The abilities of migration and invasion allow neoplastic cells to move through
surrounding tissues, enabling their dissemination through the lymphatic and blood vasculature
ultimately leading to metastatic growth in distant organs [120]. The capabilities for invasion and
metastasis enable cancer cells to break free of the primary tumor biomass and successfully
colonize new sites in the body. The acquired capacity for metastasis represents the final stage of
multi-step tumor development [103] and is the primary factor responsible for cancer-related
deaths [3].
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Role of ERK Pathway in Cancer
The mitogen-activated protein kinase (MAPK) signaling cascade transmits and amplifies
signals sent from cell surface receptors to downstream transcription factors to alter gene
expression in response to external stimuli. MAPKs direct cellular responses to diverse signaling
molecules, including growth factors, pro-inflammatory cytokines, steroid hormones, and Gprotein receptor mediated ligands, and are known to regulate genes involved in proliferation,
differentiation and apoptosis. Three major MAPK pathways exist in humans, but the one
involving Erk1/2 is the most relevant to breast cancer development [121]. Signal transduction
from cell surface to nucleus requires multiple modulators in between. The Ras/Raf/Mek/Erk
cascade (Figure 1.10) couples signals from receptor tyrosine kinases to transcription factors
which regulate cell cycle progression [122].
Binding of growth factors to receptor tyrosine kinases stimulates autophosphorylation of
specific tyrosine residues on the receptor. The phosphorylated receptor then binds to the adapter
protein GRB2, which in turn recruits SOS (son of sevenless) to the membrane. SOS is a guanine
nucleotide exchange factor that displaces GDP from the Ras small GTPase, which allows for the
binding of GTP. GTP binding activates Ras which then recruits and activates Raf. Raf initiates a
protein phosphorylation cascade by first phosphorylating Mek1/2, which in turn phosphorylates
Erk1/2. Phosphorylated Erk1/2 translocates from the cytoplasm to the nucleus where it
subsequently phosphorylates a number of transcription factors, including Elk-1, which activate
expression of specific sets of target genes. Ras activity is limited by the hydrolysis of GTP back
to GDP by GTPase activating proteins. Ras is a well-known proto-oncogene and is known to be
mutationally activated in about 30% of all human cancers [122].
The involvement of MAPK activation in human breast cancer tissues was first
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documented by Sivaraman et al. back in 1997 [123]. In comparing primary breast cancers with
benign tissues using substrate based MAPK enzyme assays and immunoblotting methods, they
found that all breast cancer tissues tested exhibited markedly high levels of activated MAPK. In
1999, Sahl et al. [124] demonstrated the over-expression of activated Erk1/2 in human breast
cancers. Using substrate based enzyme assays and immunoprecipitation studies, they detected up
to a 2.5-fold increase in phosphorylated Erk1/2 in 50% of the breast tumors tested. Another study
by Von Lintig et al. [125] investigated the mechanisms for up-regulation of MAPK signaling in
breast tumors. They suggested that if the appropriate receptors are present, up-regulation of
ligands may be responsible for elevated MAPK signaling in human breast cancers. This
possibility is supported by the in vitro studies of Xing and Imagawa [126] who demonstrated that
EGF could increase activated MAP kinase in primary cultures of mouse mammary cells. These
studies, taken together, suggest that further correlation of activated MAP kinase with biological
characteristics of tumors is warranted [121]. Studies have shown that high dose exposure to
environmental carcinogens leads to ERK pathway activation [127], but whether low doses of
environmental and dietary carcinogens can induce ERK pathway activation in breast cancer
needs to be further clarified.

Role of Reactive Oxygen Species in Cancer
Reactive oxygen species (ROS) are oxygen-containing, chemically-reactive molecules
generated mainly in the mitochondria as a byproduct of oxidative phosphorylation during cellular
respiration. ROS can be produced from endogenous sources, such as from mitochondria,
peroxisomes, and inflammatory cell activation, or from exogenous sources such as chemical or
environmental agents and pharmaceuticals. ROS include O2--derived free radicals containing an
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unpaired electron, such as superoxide anion radical (O2-) and hydroxyl radical (OH-), as well as
nonradical derivatives of O2 such as hydrogen peroxide (H2O2) [128, 129].
Chemical and physical agents that produce ROS can be involved in the initiation and
modulation of the multistep carcinogenesis process. Various environmental agents including
chlorinated compounds, phorbol esters, metal ions, barbiturates, radiation and acrylonitrile have
been shown to induce oxidative stress during in vitro and in vivo studies. Oxidative stress may
cause DNA, protein and lipid damage, leading to chromosomal instability, genetic mutation, and
alteration of cell growth that may contribute to cancer development [129]. Oxidative DNA
damage is a major source of mutations in living organisms, with more than one hundred
oxidative DNA adducts having been identified [130-133]. Accordingly, several recent studies
have demonstrated an important role for ROS in tumor development in various cancer types
[134-137]. High-dose exposure to carcinogens has been shown to produce ROS in some studies
[138-140], but the effect of low-dose environmental carcinogens in ROS production needs
further evaluation.
In addition to their effect on inducing oxidative stress and damage, ROS can also
function as signaling molecules. Growing evidence suggests that the production of ROS is tightly
regulated in mammalian cells and that these redox agents serve as intracellular signaling
molecules involved in various pathways, including the Ras/ERK pathway. Although the
mechanisms are not fully understood, ROS and Ras GTPase appear to exist in a feedback loop in
which ROS function as effector molecules to stimulate Ras activation and Ras functions as a
positive regulator of ROS production. Active Ras signaling can contribute to ROS generation via
ERK pathway-mediated activation of NADPH oxidase (Nox) enzymes, which are the major
source of ROS production outside of the mitochondria and will be discussed in further detail
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below. ROS have been shown to promote Ras activation by stimulating dissociation of GDP and
many small GTPases in the Ras superfamily were found to have redox-active motifs important
for ROS-mediated regulation [141]. Additionally, Kerzee and Ramos demonstrated that
activation of Ras by oxidative carcinogen metabolites involves a redox signaling mechanism
[142]. ROS has also been shown to stimulate activation of the ERK pathway in a Rasindependent manner via p38 MAPK in neutrophils [143]. The mutual interplay between ROS
and the Ras/ERK pathway and its involvement in cancer development and progression represents
a promising area in cancer research and warrants further investigation.

NADPH-oxidase 1
NADPH oxidases are a family of enzymes with seven isoforms (Nox-1-5 and DUOX1-2)
that produce reactive oxygen species by transporting electrons across membranes, thereby
reducing oxygen to superoxide. The Nox-1 isoform is expressed in a variety of cell types
including epithelial cells, endothelial cells, retinal pericytes, osteoclasts and vascular smooth
muscle cells [144], and has been implicated in the etiology of several diseases [144-150]. For
instance, ROS produced by Nox-1 enzyme activity are known to function in angiotensin IImediated redox signaling pathways in vascular cells and thus participate in the pathogenesis of
cardiovascular disease [145].
Evidence is also mounting for the involvement of Nox-1 in various cancers. High
expression of Nox-1 has been reported in cases of colon cancer where it may function to
stimulate NF-kappaβ-dependent anti-apoptotic pathways in colon tumor cells [146,147]. Nox-1
was also found to be highly expressed in breast and ovarian tumors, where deregulation of Nox-1
redox signaling reportedly contributed to tumorigenesis [148]. More recently, Pervin et al.
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demonstrated that oxidative stress induced through Nox-1 activity promotes breast tumor
formation by down-regulating survivin, a member of the inhibitor of apoptosis (IAP) family that
is highly expressed in aggressive triple-negative breast tumors and confers these tumors with
increased survival, angiogenesis and drug resistance [149]. Over-expression of Nox-1 stimulated
cell growth and proliferation and was found to induce a transformed phenotype in mouse
fibroblasts, which translated to increased tumorigenicity in nude mice models [150].
Furthermore, Nox-1 was found to participate in the angiogenic switch by up-regulating VEGF
expression and inducing matrix metalloproteinase activity, thus increasing the vascularity of
tumors in a mouse model of prostate cancer [151]. Further research revealed that Nox-1 can also
downregulate the expression and activity of the anti-angiogenic nuclear receptor peroxisome
proliferator-activated receptor α (PPARα) and contributes to angiogenesis in mouse models of
melanoma and Lewis lung carcinoma [144]. Since Nox-1 expression is induced through the RasERK pathway [152], it plays an important role in the interplay that occurs between ERK pathway
activation and ROS production and may function to maintain and augment cancer-associated
properties in breast epithelial cells.

Cancer Stem Cells
Stem cells are distinguished from other cell types based on their ability to self-renew,
sometimes after long periods of inactivity, and their capability to differentiate into specialized
tissue-specific cell types. Stem cells undergo a special type of asymmetric cell division in which
one of the daughter cells differentiates into a specialized cell type while the other retains stem
cell capabilities. In this way, the pool of stem cells in the body remains constant [153]. The other
defining property of stem cells is their “potency”, which refers to their ability to differentiate into
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various types of specialized cells. Early embryonic stem cells are totipotent and able to give rise
to any cell type in the body including placental cells. Later embryonic stem cells are pluripotent
and able to give rise to any tissue type excluding placenta. Adult stem cells are considered to be
multi- or unipotent and are able to develop into a few or only one type of cell, respectively [154].
Cancer develops when normal cells aberrantly gain certain characteristics including stemlike properties, such as existing in an undifferentiated state and exhibiting extensive self-renewal
or “immortality” [153, 155]. The stem-cell model for cancer progression predicts that tumors
consist of different cell types with different capacities for self-renewal and proliferation.
Subsequently, only small subpopulations of stem-like cancer cells have the capacity to initiate
tumor growth and reproduce the various cell types comprising the tumor [155].
The past decade has accumulated tremendous evidence for the involvement of stem cells
in cancer development. Cancer stem cells may arise from the mutational transformation of
normal stem cells via aberrant activation of self-renewal promoting signaling pathways, or of
differentiated cells via a process known as epithelial-to-mesenchymal transition (EMT), which
will be discussed in further detail below [155]. It has been postulated that existing stem cells may
be preferential targets of initial oncogenic mutations because they are the only long-lived
populations in most tissues and are therefore exposed to more genotoxic stresses than their
shorter-lived, differentiated progeny [153, 156]. Further support for the stem-cell model for
cancer progression is provided by the observation of tumor heterogeneity: even though most
tumors arise from a single cell, not all the cells within a tumor are identical suggesting that a
single cell gave rise to different cell types [155, 156]. Additionally, cancer stem cells are highly
enriched for the ability for reform tumors following transplantation relative to bulk tumor cells.
Importantly, cancer stem cells often exhibit resistance to traditional chemotherapies, making it
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necessary to kill or differentiate cancer stem cells in order to fully eradicate cancer [153, 155,
156].

Mammary Stem Cells and Breast Cancer
Although their involvement in cancer is virtually ubiquitous, stem cells have been
extensively characterized in breast cancer development [155]. The mammary gland is a dynamic
organ which undergoes significant developmental changes during puberty, pregnancy and
lactation. Mammary stem cells provide the source of cells necessary for normal growth of the
mammary gland during puberty and gestation but also play an important role in carcinogenesis of
the breast [157-159]. The isolation and characterization of mammary stem cells has been
hindered because of the scarcity of suitable markers and lack of adequate systems to maintain the
stem cells in an undifferentiated state [158].
A decade ago, Al Hajj et al. became the first to identify tumorigenic mammary stem cell
markers [160]. They found that only a small population of breast cancer cells had the ability to
form new tumors. They identified and isolated these tumor-initiating cells as having CD44+
CD24-/low Lineage- cell surface marker expression and demonstrated their ability to generate
tumors when injected into nude mice at numbers as low as 100 and to reproduce all the different
types of cells present in mature tumors [160]. A major advancement in the field was achieved
when Dontu et al. cultured mammary stem cells as anchorage-independent colonies in
suspensions under low serum conditions, creating spheroids termed mammospheres [161], which
will be discussed in further detail below.
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Identification and Isolation of Mammary Stem Cells
Recent advancements in stem cell research have made it possible to identify and isolate
mammary stem cells at better efficiency than ever before. There are various markers and
characteristics used to differentiate them from other surrounding cells.

Mammospheres
When grown in anchorage independent conditions, normal epithelial cells undergo a
special type of apoptosis called anoikis that occurs when the cells are detached from the ECM
[162]. However, when undifferentiated multi-potent populations of mammary cells are grown in
suspension under low serum conditions, they form discrete spheroid clusters known as
mammospheres. Mammospheres are enriched in progenitor cells and after several passages the
mammosphere consists mostly of stem cells [161].

ALDH Activity
Ginestier et al. showed that normal and cancerous mammary epithelial cells exhibiting
stem/progenitor properties also had increased activity of aldehyde dehydrogenase (ALDH), a
polymorphic enzyme responsible for the oxidation of aldehydes to carboxylic acids. They found
that high ALDH activity can be used to identify tumorigenic mammary cells capable of selfrenewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.
Additionally, high expression of ALDH in breast carcinomas was correlated with poor prognosis.
This finding offers an important new tool for the study of normal and malignant breast stem cells
and facilitates the clinical application of stem cell concepts [163].
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Immunostaining
Immunostaining and cell sorting based on surface marker expression is a widely used
technique to enrich the population of stem cells. Stem Cell Antigen-1 (SCA-1) has been used to
identify mammary stem/progenitor cells [164]. Mammary stem cells have also been identified
using the cell surface markers CD44+ CD24-/low Lineage- which are seen to be over expressed in
breast tumor cells [160].

Extensive self-renewal and multi-lineage differentiation
Stem cells derived from mammospheres have the capacity for extensive self-renewal and
can differentiate into various types of cells. When they are grown on collagen under various
conditions, such as in 2D culture systems, matrigel or in the presence of prolactin, these stem
cells can generate the entire repertoire of cell types found in mammary tissue by differentiating
into alveolar, acinar or ductal structures [158].

Epithelial-to-Mesenchymal Transition
Epithelial-to-mesenchymal transition (EMT) is a developmental regulatory program that
can become aberrantly activated in transformed epithelial cells, conferring cells with increased
migratory and invasive capabilities and stem-like properties [103]. EMT involves an orchestrated
sequence of events in which cell-cell and cell-ECM interactions are disrupted to release
epithelial cells into the surrounding tissue. The cytoskeleton is reorganized to facilitate
movement through the ECM and a new transcriptional program is activated to maintain the
mesenchymal phenotype [164]. During EMT, epithelial cells undergo multiple physical and
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biochemical changes including alterations in morphology, cellular architecture, adhesion and
migration capacity that enable them to assume a mesenchymal cell phenotype resulting in
enhanced invasiveness, elevated resistance to apoptosis, and greatly increased production of
ECM components [165]. Induction of the EMT program is detected primarily by measuring
expression of associated molecular markers (Figure 1.11) including increased expression of Ncadherin and Vimentin, nuclear localization of β-catenin, and increased production of
transcription factors such as Snail, Slug, Twist, ZEB1/2 and E47 which inhibit production of Ecadherin. Phenotypic markers for EMT include increased cell motility, migration and threedimensional invasion, as well as resistance to anoikis and apoptosis [166]. A summary of known
EMT markers are listed in Table 1.2.
Although induction of EMT has been shown to be highly tissue- and cell type-specific,
some of the general cytoplasmic signal transduction pathways involved in EMT (Figure 1.12)
have been fairly well defined [167]. The binding of the cytokine transforming growth factor-β
(TGF-β) to its cell surface receptors induces EMT through activation and nuclear translocation of
SMAD proteins which subsequently activate EMT-associated transcription factors Snail and
ZEB1/2 [168]. In other cases, activation of EMT involves more pleiotropic signals. ROS
produced through Nox-1 enzyme activity or in response to exposure to matrix metalloproteinases
(MMPs) play a key role in EMT by modulating signaling pathways involved in cell adhesion and
migration resulting in disruption of cell-cell adhesion, redistribution of E-cadherin, deregulation
of integrins and eventual loss of the epithelial phenotype [165, 169]. Several other oncogenic
signaling pathways including Src, Ras-MAPK, Wnt/beta-catenin and Notch have also been
implicated in EMT [170, 171]. In particular, Ras-MAPK has been shown to activate two related
transcription factors known as Snail and Slug, both of which are transcriptional repressors of E-
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cadherin and known to be involved in EMT induction [172]. Additionally, studies have shown
that activation of the phosphatidylinositol 3' kinase (PI3K)/AKT cascade may be a central
modulator of EMT due to its involvement in regulation of E-cadherin gene expression and
subcellular localization [173]. Since EMT enables transformed epithelial cells to acquire the
mesenchymal traits that facilitate metastasis, it has therefore been associated with aggressive
breast cancer subtypes and poor clinical outcome.

EMT and Cancer Stem Cells
EMT is associated with dedifferentiation of epithelial cells and has been shown to
generate cells with stem-like properties. In 2008, Mani et al. reported that the induction of EMT
in immortalized human mammary epithelial cells (HMLEs) resulted in the acquisition of
mesenchymal traits and the expression of stem cell markers [174]. Additionally, they found that
stem-like cells isolated from human mammary glands or mammary carcinomas expressed EMTassociated markers. Furthermore, transformed human mammary epithelial cells that have
undergone EMT have enhanced ability form mammospheres, soft agar colonies and tumors.
These findings illustrate a direct link between the induction of EMT and the acquisition of
epithelial stem-like properties [174].
Several studies have suggested the importance of environmental carcinogens in activation
of EMT [175-177] and generation of cancer stem cells [178]. The ability to identify and target
cancer stem cells in therapy is a fast growing research area; therefore it is important to identify
the origin of cancer stem cells and role of EMT during the precancerous stages of cancer
progression induced by chronic exposure to environmental and dietary cracinogens. This may
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help to prevent the formation of cancer stem cells and might be a powerful tool in reducing the
risk of cancer occurrence and relapse in patients.

Dietary Cancer Prevention
Broad geographical variation in breast cancer incidence and mortality rates is thought to
be the result of differences in lifestyle and environmental factors, including diet [179, 180].
Dynamic studies that link changes in cancer occurrence within countries to environmental or
dietary changes have suggested that diet and other lifestyle factors can substantially influence
cancer risk [181]. According to Doll and Peto, dietary factors may contribute to an estimated
one-third of all cancer-related deaths [179]; however, this estimate can vary from 10% to 70%
[182]. The World Health Organization has estimated that at least 30-40% of all cancer-related
deaths are preventable [183]. Numerous studies have indicated that high intake of fruits and
vegetables is associated with decreased risk of various cancers including pancreatic, lung, colon,
breast, cervical, esophageal, oral, stomach and bladder [184].
Naturally-occurring agents in dietary sources have been intensely investigated for the
intervention of various diseases including cancer due to their low toxicity and ease of availability
[185]. Research over the last decade has identified multiple bioactive compounds in fruits and
vegetables that can reduce the occurrence of various cancers [186]. Given the important role of
diet in cancer prevention, effective and practical chemopreventive strategies need to be
developed and should focus on high-risk populations, such as smokers [187].
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Chemopreventive Compounds in Fruit, Vegetables, Spices and Tea
Prevention of cancer through use of chemical intervention regimes, or
“chemoprevention”, is an emerging field with broad implications for influencing cancer
incidence especially among high risk groups. Many potentially chemopreventive compounds
have been identified in dietary sources, some of which are listed in Table 1.3. Fruits, vegetables,
spices and tea contain classes of primary metabolites such as vitamins (vitamin C, vitamin D,
pro-vitamin A, folate) and minerals (calcium, magnesium, selenium, zinc) as well as secondary
metabolites such as phytochemicals (flavonoids, carotenoids, phenolics polyphenols, terpenoids,
alkaloids) that behave as bioactive molecules and provide substantial health benefits beyond
basic nutrition [186, 188]. These molecules can block any stage of the multi-step oncogenic
process by exerting antioxidant, anti-proliferative, anti-inflammatory, anti-angiogenic or proapoptotic effects, mediated by various signal transduction pathways (Figure 1.13) [188].
Carotenoids, such as beta-carotene and lycopene, are commonly found in orange- or redpigmented vegetables and fruits including sweet potatoes, carrots, pumpkin, tomatoes, red
peppers, papaya, mango and cantaloupe [186]. Other carotenoids, such as leutin, are found in
dark leafy greens such as spinach and kale. Carotenoids act as chemopreventive agents through
biological activities such as antioxidant activity, immune enhancement, protection against
cellular mutagenesis, or cell cycle arrest, but evidence for their involvement in breast cancer
prevention has been inconclusive [188]. Organosulfur compounds, such as dithiolthiones and
isothiocyanates found in cruciferous vegetables like broccoli, cabbage and cauliflower, and
diallyl sulfides and allyl methyl trisulfides found in onions, garlic, leeks and chives, can increase
the activity of enzymes involved in the detoxification of carcinogens, prevent DNA adduct
formation and induce cell cycle arrest. These compounds have shown promise as preventive
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agents against breast cancer as they have demonstrated anti-proliferative and pro-apoptotic
effects on breast cancer cells [188, 189]. The antioxidants vitamin C, found in citrus fruits,
papaya, strawberries, bell peppers, kale and broccoli, and vitamin D, found in mushrooms, dairy
products and cereals, protect cell membranes and DNA from oxidative damage. Vitamin C may
further help prevent cancer via its ability to scavenge and reduce nitrite, thereby reducing
substrate for the formation of nitrosamines [190]. Curcumin, a naturally-occurring pigment and
major component of the spice turmeric, possesses potent antioxidant and anti-inflammatory
activity and prevents carcinogenesis by inhibiting genes associated with proliferation and
metastasis, inducing cell cycle arrest or inducing apoptosis. Curcumin had been shown to be
effective in preventing prostate and colorectal cancers; however, its therapeutic effects on breast
cancer remain to be determined [188].
Flavonoids, such as querticin, kaempferol and catechins, are polyphenolic antioxidants
most commonly found in fruits, tea, soybeans and wine [188]. In addition to their antioxidant
activity, flavonoids also protect against carcinogens by increasing the pump-mediated efflux of
certain carcinogens from cells [191] or by inducing detoxification enzymes [192]. Soybeans
contain genistein, an isoflavonoid and phytoestrogen that has been shown to reduce the risk of
breast cancer by decreasing the activation of carcinogens or by acting as a negative regulator of
protein tyrosine kinase and estrogen receptor signaling in breast cancer cells [188]. Fruit,
vegetables, and legumes are also major sources of dietary fiber, which has been widely accepted
as a dietary protective agent against colon cancer [193].
Various dietary sources have different bioactive compounds that help prevent cancer
through diverse mechanisms. Therefore, a balanced diet is recommended for cancer prevention
[194]. In this study we have examined the importance of the green tea catechins (-)-epicatechin-
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3-gallate (ECG) and (-)-epigallocatechin-3-gallate, as well as the plant sterol ergosterol and the
rare plant amino acid mimosine in the prevention of chronic breast cell carcinogenesis.

Green Tea
Green tea is made from leaves of the Camellia sinesis plant that have undergone little to
no oxidation during processing. It is the most globally consumed beverage in the world after
water and is a traditional drink in many Asian countries, but is also popular in North Africa, the
United States and Europe [195, 196]. Green tea contains characteristic polyphenolic compounds
called catechins. The four major catechins present in green tea are (-)-epigallocatechin-3-gallate
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), and (-)-epicatechin (EC)
in a typical composition of 10-15% EGCG, 6-10% EGC, 2-3% ECG, and 2% EC [196]. The
polyphenolic structure of green tea catechins (GTCs) allows electron delocalization to quench
free radicals including reactive oxygen species. GTCs are also strong chelators of free metal ions
which prevents the formation of ROS [197].
Accumulating evidence from animal studies has demonstrated that tea and tea
polyphenols have an inhibitory effect on tumor formation and growth in various organs including
the mammary gland [198-202]. GTC extract is able to suppress rat mammary carcinogenesis
induced by 7,12-dimethylbenz[α]anthracene and N-methyl-nitrosourea and exhibits antiproliferative and pro-apoptotic effects in human breast cancer cells in vitro [200, 201]. The
inhibitory function of GTCs is associated with antioxidant activity, decreased cell proliferation,
increased apoptosis and suppression of angiogenesis [197]. Epidemiological studies have not yet
yielded conclusive evidence on the protective effect of tea consumption against the development
of cancer in humans [197, 203-206], however some epidemiological and clinical data suggests
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that regular consumption of GTCs can suppress breast cancer recurrence and development of
colon cancer from premalignant lesions [207-209].
Although EGCG is the most commonly studied preventive GTC [197], some studies have
shown that ECG can be more effective than EGCG in intervention of carcinogenesis using
various cellular models [112, 210, 211]. In the present study, we examined the preventive
activity of ECG and EGCG individually and in combination to suppress breast cell
carcinogenesis chronically induced by combined environmental and dietary carcinogens. ECG
and EGCG have similar molecular masses, 442.37 and 458.37 g/mol respectively, indicating
similar absorption efficiencies that will result in comparable bioavailability [197]. Since ECG is
present in much lower concentrations than EGCG in green tea or green tea extract, additional
supplementation with pharmacological concentrations of ECG may be considered for long-term
prevention of breast cancer.

Epicatecin-3-gallate (ECG)
Like all catechins, epicatechin gallate (ECG) is a flavan-3-ol with four additional
hydroxyl groups and two chiral carbons (Figure 1.14A). ECG can intervene in multiple cell
signaling pathways and has various molecular targets, which likely act together to reduce the risk
of carcinogenesis. The anti-carcinogenic mechanisms of ECG include inhibition of CYP450
enzymes that metabolize carcinogens to active compounds, activation of detoxification and
antioxidant enzymes, arrest of cell cycle progression, induction of pro-apoptotic and antiinflammatory signaling and mediation of metastasis [212-216]. Many of these effects may be due
to its direct or indirect interaction with numerous molecular targets such as NSAID activated
gene-1 (NAG-1), activator protein 1 (AP-1), 5α-reductase and platelet derived growth factor
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(PDGF) [217]. By chelating copper and zinc metals ions, ECG may also inhibit the enzymatic
activity of RNase A and MMPs, which are important cofactors for angiogenesis and metastasis.
Structure and function analysis revealed that the gallate moiety of ECG is important for
mediating these inhibitory effects and may enhance its chemopreventive ability [216].

Epigallocatechin-3-gallate (EGCG)
Epigallocatechin-3-gallate (EGCG) is the ester of epigallocatechin and gallic acid
(Figure 1.14B). EGCG is the major component of the polyphenolic fraction of green tea
accounting for approximately 15% of the overall catechin content [197]. EGCG is a potent
scavenger of free radicals which protects cellular components from oxidative damage and a
number of studies have demonstrated its anti-mutagenic, anti-tumorigenic, anti-angiogenic, antiproliferative and pro-apoptotic effects on mammalian cells in vitro and in vivo. Increasing
evidence indicates that EGCG can be effective against brain, prostate, cervical and bladder
cancers [218-220]. Research suggests that EGCG may suppress carcinogenesis through
inhibition of MAP kinases and growth factor-mediated cell signaling, and activation of AP-1,
nuclear factor-B (NF-kappaB), topoisomerase I and MMPs [221]. EGCG has also been shown to
inhibit the anti-apoptotic protein Bcl-xl, which has been implicated in cancer cell survival [222].
Therefore, EGCG is a dynamic anticancer agent which provides convincing evidence to support
the anticancer potential of green tea.
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Ergosterol
Wild-growing and cultivated mushrooms are consumed in many countries around the
world often as a delicacy. Ergosta-5,7,22-trien-3β-ol, or simply ergosterol, is a sterol found
exclusively in fungi and forms the major constituent of the fungal cell membrane serving the
same purpose as cholesterol in animal cells (Figure 1.15A) [223]. Ergosterol is a provitamin that
is converted by UV irradiation to Vitamin D2; subsequently, mushrooms exposed to UV light
contain 2-4 times the Food and Drug Administration’s daily recommendation of Vitamin D
[224]. Common dietary sources of ergosterol include mushrooms of the Agaricus bisporus
(white button or portobello), Lentinula edodes (shiitake), Pleurotus ostreatus (oyster mushroom)
and Tuber (truffle) species [223], as well as products made with yeasts such as soy sauce, bread
and beer [225-227].
Ergosterol and its derivatives, including ergosterol peroxide, possess immunosuppressive,
anti-inflammatory, anti-viral and anticancer activities in vitro and in vivo. High mushroom intake
is associated with lower risk of cardiovascular disease due in part to the anti-inflammatory and
antioxidant effects of ergosterol [228]. There is solid evidence for the potential of ergosterol as
an anticancer agent. In a two stage experimental carcinogenesis study, ergosterol extracted from
Japanese edible mushroom Hypsizigus marmoreus exhibited inhibitory effects against 12-Otetradecanoyl-phorbol-13-acetate (TPA)-induced ear and skin inflammation and tumor
promotion in mice [229, 230]. Ergosterol peroxide suppressed the proliferation rates of a variety
of tumor cell lines by up to 40% [231]. Ergosterol has also been identified as a protective agent
against the promotion of carcinogen-induced bladder tumors in rats [232].
The mechanism of ergosterol’s anticancer activity has not been fully elucidated, but is
thought to be due in part to direct inhibition of angiogenesis in solid tumors. Using two in vivo
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models, Takaku et al. showed that intraperitoneal administration of ergosterol inhibited
neovascularization in a mouse model of Lewis lung carcinoma and in female C57BL/6 mice
injected subcutaneously with Matrigel containing proangiogenic factors [233]. Ergosterol
peroxide was also shown to inhibit angiogenesis in multiple myeloma cells by targeting the
JAK2/STAT3 signaling pathway and inhibiting subsequent activation of VEGF [234]. Moreover,
ergosterol peroxide and ergosterol were found to suppress the growth of colon adenocarcinoma
cells through inhibition of MAPK phosphorylation and block lipopolysaccharide (LPS)-induced
inflammatory responses in macrophages through inhibition of NF-κB transcriptional activity
[235]. Additionally, these compounds have exhibited cytotoxicity against human pancreatic and
breast cancer cell lines [236]. There is also evidence that ergosterol peroxide may attenuate
microRNA-mediated chemoresistance in tumor cells by selectively killing aggressive cancer
cells [237]. However, there is scarcity of knowledge regarding the ability of ergosterol to act as a
preventive agent against the development of breast cancer.

Mimosine
Mimosine (β-[N-(3-hydroxy-4-oxypyridyl)]-R-aminopropionic acid), also known as
leucenol, is a rare alkaloid amino acid found exclusively in tropical legumes of the Mimosa and
Leucaena genera. It is a non-proteinogenic, plant-origin, free amino acid structurally analogous
to tyrosine (Figure 1.15B) that can cause toxicosis in non-ruminant animals at high
concentrations by causing renal and liver failure [238]. The leaves, seeds and fruits of various
Leucaena species are widely consumed throughout India, Indonesia, Central America and
Thailand, though as minor constituents of the diet they do not often cause mimosine toxicity in
humans [239].
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Some of the mechanisms by which mimosine exerts its toxic action may be responsible
for its anticancer effects. Mimosine is an iron chelator that inhibits DNA synthesis and causes
cell cycle arrest in late G1 phase [238]. Mimosine arrests cell cycle progression at the G1-S phase
border prior to the onset of DNA replication [240]. Several mechanisms have been proposed to
explain the effects of mimosine on blocking cell cycle progression. At high micromolar
concentrations, mimosine has been shown to specifically inhibit expression of cyclin D1 and to
upregulate the protein expression levels of p21CIP1 and p27KIP1 cyclin-dependent kinase (CDK)
inhibitors [241, 242]. Subsequently, high doses of mimosine have been effective in reducing the
proliferation rates of several types of cancer cell lines including lung [241], cervical [243],
prostate [244] and breast cancer cells [245], as well as reducing tumor growth in vivo in mouse
xenograft models of human non-small cell lung carcinoma [246] and pancreatic cancer [247].
The metal chelating function of mimosine is closely associated with its toxicity and antiproliferative effects. Iron chelation by mimosine disturbs the action of metal-containing enzymes
causing inhibition of some biological reactions [239] including translation of mRNA [243] and
the initiation and elongation steps of DNA replication [248]. Accordingly, inhibition of DNA
synthesis by the iron chelating function of mimosine was found to block cell cycle progression in
breast cancer cells [245] and induce apoptosis in mouse leukemia cells [249] and human
pancreatic cancer cells [247]. Although much research has focused on the use of high doses of
mimosine to block proliferation or induce apoptosis in cancer cells, little work has been
undertaken to evaluate the effectiveness of mimosine at low non-cytotoxic doses to inhibit
cellular carcinogenesis.

47

Cancer Prevention Strategies using Combined Dietary Agents
Prevention strategies making use of combined dietary agents with different molecular
mechanisms are advantageous over those using individual agents due to higher efficacy and
lower toxicity. Since carcinogenesis occurs in multiple stages, a variety of agents with distinct
modes of action targeting different signaling pathways are needed to effectively suppress this
complex process. Accordingly, there are many lines of evidence that support the use of combined
dietary agents for the prevention of various malignancies. For instance, consuming a variety of
chemopreventive agents from fruits, vegetables and soy is associated with decreased risk of
breast cancer among postmenopausal women in Singapore [251] and combining vitamin E with
vitamin C or β-carotene more effectively reduced UV-induced skin inflammation in human trials
and is associated with decreased risk of melanoma and non-melanoma skin cancers [252].
Dietary phytochemicals can inhibit or delay carcinogenesis by displaying antioxidant
activity, regulating inflammatory or proliferative signaling, or by inducing apoptosis. Therefore,
one effective strategy for cancer prevention is to combine dietary agents with differing methods
of antioxidant activities, such as combining molecules which scavenge ROS with molecules that
prevent generation of ROS. Combining 1-acetoxychavicol acetate (ACA), a phenylpropanoid
occurring in the rhizomes of Alpinia galangal which is consumed in Southeast Asia, with
superoxide dismutase (SOD), an ROS-scavenging enzyme present in cereal grains and
cruciferous vegetables, synergistically suppressed ROS generation in inflammatory leukocytes
compared to individual agents. The high efficacy of this combination is due to the
complementary effects of ACA, which prevents ROS generation by inhibiting Nox family
enzymes, and SOD which neutralizes ROS [253]. Similar results were seen with ACA/caffeic
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acid, EGCG/SOD, EGCG/ genistein, EGCG/benzyl isothiocyanate and benzyl isothiocyanate/
genistein combinations [250, 253].
Another effective strategy is to combine dietary agents with complementary antiinflammatory functions. In a rat model of human prostate cancer, animals fed a combination of
soy protein and green tea had reduced occurrence of prostate malignancy markers and
hyperplasia, lower number of inflammatory cells infiltrated into the prostate and decreased
protein expression of inflammatory cytokines in the prostate. Interestingly, none of these effects
were seen in animals fed individual agents. Mechanistically, Hsu et al. found that the soy/green
tea combination suppressed prostate cancer development by mitigating chronic inflammation
through modulation of NF-kappaβ signaling. Bioactive compounds in green tea decreased the
DNA binding activity of the p50 subunit of NF-kappaβ and bioactive compounds in soy restored
levels of the NF-kappaβ inhibitor p-IκBα to that of the control group [254]. Paradoxically, green
tea catechin EGCG has also been shown to increase inflammatory cytokines produced by
RAW264.7 macrophages. However, the cytokine-inducing properties of EGCG were completely
masked by combined treatment with the soybean isoflavonoid genistein resulting in marked
suppression of pro-inflammatory signaling [250]. This result highlights another important
advantage of combination strategies; combining one dietary agent with another can abolish or
attenuate potential side-effects while still increasing efficacy.
A third common and effective strategy is to combine dietary agents that can increase
apoptotic death in cancer cells. In the rat model of prostate cancer mentioned above, Hsu et al.
also found that the rats fed the soy/green tea combination showed increased apoptotic signaling
in prostate tissues compared to animals fed individual agents. The combination of soy and green
tea resulted in increased expression of pro-apoptotic Bax and decreased expression of anti-
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apoptotic BcL-2 and cellular inhibitor of apoptosis 1 (cIAP-1) [254]. In another animal model of
prostate cancer, TRAMP (transgenic adenocarcinoma of the mouse prostate) mice fed a
combination of tomato powder and soy germ showed increased apoptotic index (AI) in the
prostate epithelium contributing to reduced prostate cancer incidence compared to mice fed
individual agents [255]. In vitro experiments using normal and cancerous human colon cell lines
revealed that combinations of indoles and isothiocyanates from cruciferous vegetables more
effectively induced apoptosis in colon cancer cells, but not in normal cells, when compared to
individual agents. Interestingly, a combination of indole and isothiocyanate agents also markedly
reduced DNA damage caused by B[α]P [256].
Numerous other strategies have been designed to maximize cancer suppression by
exploiting the various preventive mechanisms of dietary agents. Zhou et al. determined that tea
and soy combinations contribute to breast and colon cancer prevention by targeting various
metabolic syndrome elements in mice in a synergistic manner resulting in reprogramming of
aberrant metabolic signaling [257]. Other research has indicated that a combination of
polyphenols from green tea and sulforaphane from cruciferous vegetables, which inhibit DNA
methyltransferases (DNMTs) and histone deacetylases (HDACs) respectively, results in
epigenetic modifications that reactivate ERα-receptor signaling in ERα-negative breast cancer
cells conferring them with increased drug sensitivity [258]. In a rat model of colorectal cancer, a
combination of green tea and selenium was more effective in decreasing aberrant crypt foci
formation and all tumor-associated endpoints through targeting different cellular responses to
oncogenic DNA lesions [259]. In the present work, we propose that a combination of dietary
agents is the best course of action against breast cell carcinogenesis induced by multiple
environmental and dietary agents.
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Table 1.1
PhIP content in cooked meats

Meat type

Beef (1.5 cm thick)

Cooking variation

PhIP ng/g +/- SD

Fried – medium rare (51ºC)

0.29 +/- 0.14

Fried – well-done (63ºC)

0.73 +/- 0.02

Fried – very well-done (74ºC)

7.33 +/- 0.11

Fried – medium (75ºC)

0

Fried – well-done (85ºC)

2.4

Fried – medium (63ºC)

0.37 +/- 0.06

Fried – well-done (83ºC)

7.82 +/- 1.13

Fried – medium (51ºC)

0

Fried – well-done (58ºC)

3.96 +/- 0.13

Fried – lightly browned (63ºC)

0.2 +/- 0.005

Fried – well-done (79ºC)

17.54 +/- 0.17

Fried – lightly browned (42ºC)

0

Fried – well browned (70ºC)

0.61 +/- 0.06

Fried – lightly cooked

0.11 +/- 0.002

Fried – well cooked

1.93 +/- 0.37

Lamb Chop

Pork (2 cm thick)

Mince Beef Patty (2 cm thick)

Chicken (2.5 cm, no skin)

Sausage

Bacon, middle

Adapted from Wikipedia
(http://en.wikipedia.org/wiki/2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine)
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Table 1.2
List of known EMT markers

Proteins that increase in abundance

Proteins whose activity increases

N-cadherin

ILK

Vimentin

GSK-3β

Fibronectin

Rho

Snail1 (Snail)

Proteins that accumulate in the nucleus

Snail2 (Slug)

β-catenin

Twist

Smad-2/3

FOXC2

NFκB

Sox10

Snail1 (Snail)

MMP-2

Snail2 (Slug)

MMP-3

Twist

MMP-9

In vitro functional markers

Integrin αvβ6

Increased migration

Proteins that decrease in abundance

Increased invasion

E-cadherin

Increased scattering

Desmoplakin

Elongation of cell shape

Cytokeratin

Resistance to anoikis

Adapted from Lee et al. (2006) J Cell Biol 172: 973-981.
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Table 1.3
List of chemopreventive compounds and their common sources

Preventive Compound

Source

Allium Compound

Onions, garlic, scallions, leeks, chives

Carotenoids

Carrots, sweet potatoes, tomatoes, dark leafy greens

Coumarins

Tonka beans, mullein, cassia, cinnamon, sweet clover

Dietary fiber

Soybeans and other legumes

Flavonoids

Green tea, wine, citrus fruits, dark chocolate

Folic acid

Green leafy vegetables, cereals

Indole-3-carbinal

Broccoli, cabbage, cauliflower, Brussels sprouts, collard greens, kale

Isoflavones

Soybeans, green beans, alfalfa sprouts, cowpeas

Isothiocyanate

Horseradish, mustard, radish, Brussels sprouts, watercress, capers

Vitamin C

Citrus fruits, chiles, broccoli, strawberries

Adapted from Rathore (2011) PhD diss., University of Tennessee.
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Figure 1.1
Worldwide incidence of breast cancer in 2008

Adapted from Susan G. Komen
(http://www.komen.org/BreastCancer/Statistics.html#worldvar)
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Figure 1.2
Stages of breast cancer

Adapted from the Society for Clinical Oncology
(http://www.asco.org/)
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Figure 1.3
Molecular subtypes of breast cancer

Adapted from Sandhu et al. (2010) Lab Med. 41: 364-372.
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Figure 1.4
Risk factors for breast cancer

Adapted from Breast Cancer Organization
(http://www.breastcancer.org/risk/factors)
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Figure 1.5
Environmental or non-hereditary potential cancer-causers

Adapted from Cancer News in Context
(http://www.cancernewsincontext.org)
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A)

B)

C)

Figure 1.6
Chemical structure of carcinogens
(A) Structure of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
(B) Structure of benzo[α]pyrene (B[α]P)
(C) Structure of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP)

Adapted from Wikipedia
(commons.wikimedia.org)
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Figure 1.7
Hallmarks of cancer

Adapted from Hanahan et al. (2011) Cell. 144: 646-674.
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Figure 1.8
Emerging hallmarks and enabling characteristics

Adapted from Hanahan et al. (2011) Cell. 144: 646-674.
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Figure 1.9
Precancerous model of cancer progression

Adapted from Rathore et al. (2012) Carcinogenesis. 33: 174-183.
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Figure 1.10
Ras signaling and ERK pathway activation

Adapted from Schubbert et al. (2007) Nat Rev Cancer 7: 295-308.

93

Figure 1.11
Changes during Epithelial-to-Mesenchymal Transition

Adapted from Thiery and Sleeman (2006) Nat Rev Mol Cell Biol 7: 131-142.
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Figure 1.12
Pathways activated during EMT

Adapted from Lee et al. (2006) J Cell Biol 172: 973-981.
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Figure 1.13
Anticancer mechanisms of dietary agents

Adapted from German Cancer Research Center
https://www.dkfz.de/en/index.html
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A)

B)

Figure 1.14
Chemical structure of green tea catechins
(A) Structure of (-)-epicatechin-3-gallate (ECG)
(B) Structure of (-)-epigallocatechin-3-gallate (EGCG)

Adapted from Wikipedia
(commons.wikimedia.org)
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A)

B)

Figure 1.15
Chemical structure of ergosterol and mimosine
(A) Structure of ergosta-5,7,22-trien-3β-ol (ergosterol)
(B) Structure of (2S)-2-Amino-3-(3-hydroxy-4-oxopyridin-1-yl)propanoic acid (mimosine)

Adapted from Wikipedia
(commons.wikimedia.org)
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CHAPTER 2

Chronic Exposure to Combined Carcinogens Enhances Breast Cell
Carcinogenesis with Mesenchymal and Stem-like Cell Properties
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Research described in this chapter is a slightly modified version of an article that has been
accepted for publication in PLoS ONE by Lenora Ann Pluchino and Hwa-Chain Robert Wang

Lenora Ann Pluchino and Hwa-Chain Robert Wang. Chronic Exposure to Combined
Carcinogens Enhances Breast Cell Carcinogenesis with Mesenchymal and Stem-like Cell
Properties. (PLoS ONE, Accepted)

In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing
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Abstract
Most breast cancers occur sporadically due to long-term exposure to small quantities of
multiple carcinogens present in the environment and diet via a multi-step process involving the
progressive transformation of cells from a non-cancerous stage to pre-cancerous and cancerous
stages. To understand how multiple carcinogens act together to induce cellular carcinogenesis,
we studied the activity of environmental carcinogens 4-(methyl-nitrosamino)-1-(3-pyridyl)-1butanone (NNK) and benzo[α]pyrene (B[α]P), and dietary carcinogen 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine (PhIP) using our breast cell carcinogenesis model. Our study
revealed, for the first time, that combined NNK and B[α]P (NB) enhanced breast cell
carcinogenesis chronically induced by PhIP in both non-cancerous and cancerous breast cells.
Co-exposure to NB and PhIP was more potent than sequential exposure to NB followed by PhIP
in initiating and progressing carcinogenesis. Initiation of carcinogenesis was measured by
transient endpoints induced in a single exposure, while progression of carcinogenesis was
measured by acquisition of constitutive endpoints after cumulative exposures. Transient
endpoints included DNA damage, Ras-ERK-Nox pathway activation, reactive oxygen species
elevation, and increased cellular proliferation. Constitutive endpoints included various cancerassociated properties and signaling modulators, as well as enrichment of cancer stem-like cell
population and activation of the epithelial-to-mesenchymal transition program. Using transient
and constitutive endpoints as targets, we detected that a combination of the green tea catechins
ECG and EGCG, at non-cytotoxic levels, was more effective than individual agents in
intervention of cellular carcinogenesis induced by combined NNK, B[α]P, and PhIP. Thus, use
of combined ECG and EGCG should be seriously considered for early intervention of breast cell
carcinogenesis associated with long-term exposure to environmental and dietary carcinogens.
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Introduction
Breast cancer is the most common type of cancer and second leading cause of cancerrelated death among women in North America and Europe [1,2]. Over 85% of breast cancers
occur sporadically due to long-term exposure to low doses of multiple carcinogens [3–7]. This
chronic disease process involves cumulative genetic and epigenetic alterations which
progressively transform cells from a non-cancerous stage to pre-cancerous and cancerous stages
[3-6]. Since we are all exposed to various environmental and dietary carcinogens each day, it is
important to investigate how multiple carcinogens act together to induce cellular carcinogenesis.
We have developed a cellular model that mimics breast cell carcinogenesis induced by
cumulative exposures to physiologically-achievable doses of environmental and dietary
carcinogens to understand the cellular, biochemical, and molecular changes involved in cellular
carcinogenesis for the purposes of intervention.
American lifestyles involve frequent consumption of high-temperature cooked meats
containing carcinogens, such as 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), and
wide exposures to smoke and polluted air containing 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK) and benzo[α]pyrene (B[α]P). PhIP is the most abundant heterocyclic amine
found in meats cooked at high temperatures, and consumption of PhIP at microgram levels
results in systemic exposure at low nanomolar levels [8,9]. Gastric administration of PhIP
induces mammary tumors in rats [10,11], and epidemiological studies have indicated a close
association between well-done meat consumption and human breast cancer risk [12–14]. NNK,
a tobacco-specific nitrosamine ketone, can be detected at picomolar concentrations in body fluids
of tobacco users [15–17]. Although gastric administration of NNK into rats resulted in DNA
adducts and tumor development in the mammary gland [18,19], NNK is not recognized as a
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mammary carcinogen. The link between smoking and breast cancer is controversial; however,
recent studies indicate that exposure to tobacco smoke can increase breast cancer risk, especially
in post-menopausal women [20–22]. Thus, the role of tobacco carcinogens in breast cancer
needs to be clarified. B[α]P, on the other hand, is recognized as a weak mammary carcinogen.
B[α]P is a polycyclic aromatic hydrocarbon present in carbon exhaust, charcoal-barbequed
foods, and tobacco smoke; it can be found in picomolar concentrations in human fat and liver
[23–28].
Our studies have shown that NNK at100 pmol/L, B[α]P at 100 pmol/L, and PhIP at 10
nmol/L are able to induce initiation and progression of breast cell carcinogenesis [29–35]. A
single exposure to these carcinogens induces transient changes, which play essential roles in the
induction of carcinogenesis and can be used as transient endpoints to promptly reveal
carcinogenic activity. Cumulative exposures to carcinogens progressively induce cellular
acquisition of various cancer-associated properties and activation of associated pathways; these
properties are measurable constitutive endpoints used to determine the progression of cellular
carcinogenesis [29–35]. Our model also reveals increases of cancer stem-like cell populations
and activation of the epithelial-to-mesenchymal transition (EMT) program during carcinogeninduced cellular carcinogenesis [35,36]. Development of cancer stem-like cells, involving
induction of the EMT program, plays an important role in generating and maintaining premalignant and malignant lesions [37]. Thus, we also used increased cancer stem-like cell
population and induced EMT program as constitutive endpoints in our studies. We then used
these endpoints as targets to identify preventive agents, such as green tea catechins (GTCs)
epicatechin (EC), epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epigallocatechin-3-
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gallate (EGCG), at non-cytotoxic levels, capable of intervening in breast cell carcinogenesis
induced by NNK, B[α]P, or PhIP [31–36].
In this communication, we report the potency of co-exposure versus pre-exposure to
combined NNK and B[α]P (NB) with PhIP in chronic induction of breast cell carcinogenesis.
Co-exposure to NB and PhIP (NBP) induced higher levels of transient and constitutive endpoints
than pre-exposure to NB followed by PhIP. We also studied the activity of ECG and EGCG, at
non-cytotoxic levels, in suppression of NBP-induced endpoints. We determined that a
combination of ECG and EGCG was more effective than either agent alone, at equivalent doses,
in intervention of NBP-induced cellular carcinogenesis.

Materials and Methods
Cell cultures and reagents
MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and derived cell
lines were maintained in complete (CM) medium (1:1 mixture of DMEM and HAM's F12,
supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol,
20 ng/mL epidermal growth factor, and 5% horse serum) [29–36]. Human breast cancer MCF7
cells (ATCC) were maintained in DMEM supplemented with 10% heat-inactivated fetal calf
serum [34,35]. All cultures were supplemented with 100 U/mL penicillin and 100 µg/mL
streptomycin and maintained in 5% CO2 at 37°C. Stock solutions of NNK (Chemsyn, Lenexa,
KS), B[α]P (Aldrich, Milwaukee, WI), PhIP (Midwest; NCI Chemical Carcinogen Reference
Standard Repository), U0126 (Cell Signaling, Beverly, MA), and CM-H2DCF-DA (Invitrogen,
Carlsbad, CA) were prepared in DMSO; ECG, EGCG (Sigma-Aldrich, St. Louis, MO), and N-
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acetyl-L-cysteine (NAC) (Alexis, San Diego, CA) were prepared in distilled water. All were
diluted in CM medium for assays.

Chronic induction of cellular carcinogenesis
Twenty-four hours after each subculturing, human breast cells were treated with the
indicated carcinogens for 48 h as one cycle of exposure for 20 cycles. Cells were subcultured
every 3 days [29–36].

DNA Damage Assay
DNA damage was detected with a comet assay [38]. Cells were trypsinized and collected
in phosphate-buffered saline (PBS) at a density of 2 × 104 cells/ml. Cell suspension was mixed
with an equal volume of 1% low-melting agarose (Fisher, Fair Lawn, NJ) and placed on agarosecoated slides. Slides were then immersed in lysis solution (1.2 mol/l NaCl, 100 mmol/l Na2EDTA, 1% Triton X-100 and 0.3 nmol/l NaOH, pH 13) at 25º C for 1 h and rinsed three times
with alkaline buffer (2 mmol/l Na2-EDTA and 300 mmol/l NaOH) for 20 min each. After
electrophoresis in the same alkaline buffer at 20 V for 30 min, slides were stained with 2.5 µg/ml
of propidium iodide for 20 min and examined with a Zeiss fluorescence microscope (Carl Zeiss
Inc, Thornwood, NY) equipped with an excitation filter of 546 nm and barrier filter of 590 nm.
Fifty nuclei per slide were scored for tail moment (% of DNA in the tail × tail length) as a
parameter using CometScore software (Tritek Corp, Sumerduck, VA).
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Reduced dependence on growth factors
A total of 5 × 103 cells were seeded in 60-mm culture dishes and maintained in lowmitogen (LM) medium (1:1 mixture of DMEM/F12, 2 ng/mL cholera enterotoxin, 200 ng/mL
insulin, 10 ng/mL hydrocortisol, 0.4 ng/mL epidermal growth factor, and 0.1% horse serum),
containing reduced total serum and mitogenic additives to 2% of the concentration formulated in
CM medium, for 10 days to develop cell colonies [32–35].

Anchorage-independent growth
A total of 1 × 104 cells were mixed with soft agar consisting of 0.4% low-melting agarose
(Sigma-Aldrich, St. Louis, MO) in a mixture (1:1) of CM medium with 3-day conditioned
medium prepared from MCF10A cultures, plated on top of a 2% low-melting agarose base layer
in 60-mm culture dishes and maintained for 14 days to develop cell clones [32–35].

Measurement of intracellular ROS
Cultures were labeled with 5 µmol/L CM-H2DCF-DA for 1 h. Cells were trypsinized and
resuspended in PBS for analysis of reactive oxygen species (ROS) by flow cytometry, using a
15 mW, air-cooled argon laser to produce 488 nm light. DCF fluorescence emission was
collected with a 529 nm band pass filter. The mean fluorescence intensity of 2 × 104 cells was
quantified using Multicycle software (Phoenix Flow System, San Diego, CA) [32–35].
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Cellular proliferation assay
Cell proliferation was determined using the 5-bromo-2-deoxyuridine (BrdU) cell
proliferation enzyme-linked immunosorbent assay (ELISA) kit (Roche, Indianapolis, IN). A total
of 5 × 103 cells/well in 96-well culture plates were labeled with BrdU for 12 h, fixed, incubated
with peroxidase-conjugated BrdU-specific antibodies and stained with the peroxidase substrate.
Quantification of BrdU-labeled cells was determined by an ELISA reader (Bio-Tek, Winooski,
VT).

Reverse-transcription PCR
Total RNA isolated from cultures using the Absolutely RNA kit (Stratagene, La Jolla,
CA) was reverse transcribed to complementary DNA using the Verso cDNA Kit (Thermo
Scientific, Waltham, MA). The resulting cDNAs were subjected to PCR for H-Ras (forward: 5’GACGGAAT ATAAGC TGGTGG-3’; reverse: 5’-AGGCACGTCTCCCCATCAAT-3’) and βactin (forward: 5’-GGACTTCGAGCAAGAGATGG-3’; reverse: 5’-AGCACTGTGTTGGCGT
ACG-3’). PCR products were electrophoresed on agarose gels and visualized using ethidium
bromide staining.

Immunoblotting
Cell lysates were prepared in buffer (10 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100,
5 mM EDTA, 10 mM sodium pyrophosphate, 10% glycerol, 0.1% Na3VO4, 50 mM NaF, pH
7.4) [31,32]. Protein concentration in cell lysates was measured using the BCA assay (Pierce,
Rockford, IL). Equal amounts of cellular proteins were resolved by electrophoresis in 10% or
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12% sodium dodecyl sulfate-polyacrylamide gels for Western immunoblotting using specific
antibodies to detect H-Ras, phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, EpCAM, Ecadherin, MMP-9, Vimentin, and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA). Antigenantibody complexes on filters were detected by the Supersignal chemiluminescence kit (Pierce,
Rockford, IL).

Serum-independent non-adherent growth
A total of 1 × 104 cells were seeded on top of 1% agarose-coated, non-adherent 100-mm
culture plates, incubated in serum-free CM medium supplemented with 0.4% bovine serum
albumin and maintained for 10 days to develop mammospheres [35,36].

Aldehyde dehydrogenase (ALDH) assay
An ALDEFLUOR Kit (StemCell Technologies, Durham, NC) was used to detect ALDHexpressing cells [35,36]. A total of 1 × 105 cells/ml were resuspended in assay buffer, mixed with
activated Aldefluor substrate BAAA (BODIPY-aminoacetaldehyde), and incubated in the
presence and absence of the ALDH inhibitor diethylaminobenzaldehyde (DEAB) at 37º C for 40
min. Then, cells were resuspended in assay buffer for flow cytometric analysis by using a 15
mW air-cooled argon laser to produce 488 nm light. Fluorescence emission was collected with a
529-nm band pass filter. The mean fluorescence intensity of cells was quantified using
Multicycle software (Phoenix Flow System, San Diego, CA). Cells incubated with BAAA in the
presence of DEAB were used to establish the baseline of fluorescence for determining the
ALDH-expressing cell population (%) in which ALDH activity was not inhibited by DEAB.
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In vitro cell invasion and migration
The in vitro cell invasion assay was performed using 24-well Transwell insert chambers
with a polycarbonate filter with a pore size of 8.0 µm (Costar, Corning, NY). A total of 2 × 104
cells in serum-free medium were seeded on top of a Matrigel-coated filter (BD Biosciences,
Franklin Lakes, NJ) in each insert chamber. Then, insert chambers were placed into wells on top
of culture medium containing 10% horse serum as a chemoattractant. After 24 h, the invasive
ability of cells was determined by the number of cells translocated to the lower side of filters
[33–36].
The in vitro migration assay was performed using 24-well Transwell insert chambers
with a polycarbonate filter not coated in Matrigel. The migration ability of cells was determined
by the number of cells translocated to the lower side from the upper side of filters [33–36].

Cell motility wound-healing assay
Cells were seeded in 6-well plates and grown to confluence in CM medium. Cells were
rinsed with PBS and serum-starved for 15 h in DMEM/Ham’s F12 medium containing 2% horse
serum. The monolayer was then scratched with a 23-gauge needle (BD Biosciences, Franklin
Lakes, NJ) to generate wounds, rinsed with CM medium to remove floating cells, and then
maintained in CM medium. The wounded areas were examined 6, 12 and 24 h after scratches to
detect healing. The area not healed by the cells was subtracted from the total area of the initial
wound to calculate the wound healing area at time intervals of 6 and 12 h, using Total Lab
TL100 software (Total Lab, Newcastle, NE) [36].
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Statistical Analysis
The Student t test was used to analyze statistical significance, indicated by * P<0.05, **
P<0.01, and *** P<0.001; a P value <0.05 was considered significant.

Results and Discussion
Enhanced cellular acquisition of cancer-associated properties by combined carcinogens
Previous studies have shown that NNK and B[α]P exhibit comparable abilities to induce
breast cell carcinogenesis [33,34]. Combining NNK and B[α]P (NB) additively increased
degrees of all acquired constitutive cellular endpoints except tumorigenicity [33,34], indicating
that NNK and B[α]P may act as weak breast carcinogens. To detect whether NB could enhance
breast cell carcinogenesis induced by the potent breast carcinogen PhIP, we first used a comet
assay to measure the ability of these carcinogens to induce cellular DNA damage after one
exposure, which is essential for the induction of cellular carcinogenesis [37]. Exposure to
combined NB and PhIP (NBP) induced a significantly higher level of DNA damage than either
NB or PhIP (Figure 2.1A). Blockage of the ERK pathway (with the Mek-specific inhibitor
U0126) or ROS production (with the general antioxidant NAC) significantly reduced NB-, PhIP, and NBP-induced DNA damage (Figure 2.1A). These results indicate that co-exposure to NB
and PhIP was more potent than either was alone to induce DNA damage for induction of cellular
carcinogenesis, and the ERK pathway and ROS production are required for this process.
To verify whether cumulative exposures to NB and PhIP would result in enhanced
cellular carcinogenesis, we exposed MCF10A cells to NB, PhIP, and NBP for 20 cycles,
resulting in the NB20, P20, and NBP20 cell lines, respectively. NB20 cells were then exposed to
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PhIP for an additional 20 cycles, resulting in the NB20/P20 cell line. We then compared the
potency of these resulting cell lines by measuring degrees of acquired cancer-associated
properties/constitutive endpoints [29–35]. Growth factors and cellular adhesion to the
extracellular matrix are required for normal epithelial cell survival; in contrast, cancerous cells
acquire a reduced dependence on growth factors (RDGF) and anchorage-independent growth
(AIG) to increase survivability [37]. Increased ROS production and cellular proliferation are also
closely associated with cellular transformation [37]. We detected that NB20/P20 and NBP20
cells acquired higher degrees of RDGF (Figure 2.1B-1), AIG (2.1B-2), ROS content (2.1B-3),
and cellular proliferation (2.1B-4) than NB20 or P20 cells. NBP20 cells acquired higher degrees
of these endpoints than NB20/P20 cells, reaching levels comparable to malignant control
MCF10A-Ras cells, in which oncogenic H-Ras is ectopically expressed in MCF10A cells [39].
The results indicate that pre-exposure (NB20/P20) or co-exposure (NBP20) to NB significantly
enhanced PhIP-induced constitutive endpoints, with co-exposure being the most potent.
Our previous studies showed that up-regulated H-Ras gene expression, as a constitutive
molecular endpoint, and activated Ras-ERK-Nox pathway, as a constitutive biochemical
endpoint, are essential for maintaining constitutive cellular endpoints induced by PhIP [35]. In
studying if these molecular and biochemical changes were enhanced by NBP, we detected that
cumulative pre- and co-exposures to NB and PhIP resulted in highly up-regulated H-Ras gene
expression (Figure 2.1B-5), increased H-Ras protein level, and activated downstream ERK-Nox
pathway (2.1B-6) in NB20/P20 and NBP20 cells; these endpoints were up-regulated to higher
levels in NBP20 cells than in NB20/P20 cells but did not reach their counterpart levels in
MCF10A-Ras cells. These results indicate that NNK and B[α]P can enhance the ability of PhIP
to induce breast epithelial cell carcinogenesis, even though NNK is not considered a mammary

111

carcinogen, and B[α]P is considered a weak mammary carcinogen. Co-exposure to these
carcinogens is more potent than pre-exposure to induce cellular acquisition of cancer-associated
properties. The constitutive biochemical endpoints of Ras-ERK-Nox pathway activation and
ROS elevation were induced consistently with constitutive cellular endpoints and may play
important roles in maintaining cancer-associated properties in NBP-exposed cells.
To verify roles the ERK pathway and ROS may play in NBP-exposed cells, we used
U0126 to inhibit Mek and NAC to inhibit ROS in NB20/P20 and NBP20 cells. Treatment with
U0126 did not affect H-Ras expression but reduced Erk1/2 activity, Nox-1 expression (Figure
2.1C-1), ROS level (2.1C-2), and cell proliferation (2.1C-3), indicating that the ERK-Nox
pathway plays an important role in maintaining ROS production and cell proliferation in both
NB20/P20 and NBP20 cells. NAC treatment suppressed the Ras-ERK-Nox pathway (Figure
2.1C-1), ROS level (2.1C-2), and cell proliferation (2.1C-3), indicating an essential role for ROS
production in maintaining activated Ras-ERK-Nox pathway and increased cell proliferation.
These results reveal a cross-talk between the Ras-ERK-Nox pathway and ROS production,
which are necessary for maintaining increased cell proliferation, and possibly other cancerassociated properties, in NBP-exposed cells.

Enhanced acquisition of stem-like and mesenchymal cell properties by combined
carcinogens
Mammary stem-like cells are able to self-renew in serum-free media, are known to
exhibit high levels of ALDH activity, and have a unique ability to form discrete spheroid clusters
called mammospheres in non-adherent cultures [40,41]. We have reported that enrichment of
ALDH-positive cell populations and increased formation of mammospheres were induced by
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cumulative exposures to NB [36] or PhIP [35] in MCF10A cells. However, increased stem-like
cell population is not yet fully appreciated as a breast cancer-associated property. Growth of
mammospheres (serum-independent non-adherent growth, SINAG) involves the properties of
RDGF and AIG, both of which are enhanced by NBP exposure. Thus, it was important to
understand whether NBP-enhanced cellular carcinogenesis was accompanied by enhanced stemlike cell properties. As shown in Figure 2.2, mammospheres (2.2A) and ALDH-positive cell
population (2.2B) were increasingly induced in NB20, P20, NB20/P20, and NBP20 cells (NB20
< P20 < NB20/P20 < NBP20). Accordingly, cumulative co-exposures of cells to NBP resulted in
acquisition of significantly increased stem-like cell populations that should be considered a novel
cancer-associated property used to measure the progression of breast cell carcinogenesis.
The ability to develop stem-like cells is associated with activation of the EMT program
[37]. During EMT, reduction of epithelial cellular adhesion molecule (EpCAM) and E-cadherin
is associated with a loss in cell-cell adhesion [42] while an increase in matrix metalloproteinase9 (MMP-9) is involved in degradation of the extracellular matrix [37]; increased Vimentin plays
a role in filament formation and cell motility [43]. We detected that EpCAM and E-cadherin
were reduced but MMP-9 and Vimentin were increased (Figure 2.2C) in NB- and/or PhIPexposed cells, and these changes occurred consistently with degrees of increased mammosphere
formation (2.2A) and enriched ALDH-positive stem-like cell populations (2.2B). Induction of
the EMT program has been postulated to not only contribute to cellular acquisition of stem-like
properties but also increased migratory and invasive capabilities [37]. We detected that increased
degrees of cell migration (Figure 2.2D) and invasion (2.2E) were closely correlated with the
increased degrees of mammosphere formation (2.2A), stem-like cell population (2.2B), and EMT
markers (2.2C) acquired by NB- and/or PhIP-exposed cells: NBP20 > NB20/P20 > P20 > NB20.
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In addition, using a wound healing assay, we detected that increased cell motility (Figure 2.2F-1
and 2.2F-2) was also accordingly acquired by these NB- and/or PhIP-exposed cells. These results
indicate that cumulative exposure to NBP significantly enhanced cellular acquisition of stem-like
and EMT-associated markers and properties. Cellular acquisition of stem-like and EMTassociated properties should be considered as novel cancer-associated properties and constitutive
endpoints in measurement of the progression of breast cell carcinogenesis.

NBP enhanced cancer-associated properties in breast cancer MCF7 cells
To clarify whether the enhanced acquisition of cancer-associated properties induced by
NBP was limited to MCF10A cells, we exposed human breast cancer MCF7 cells to NBP, NB,
and PhIP. A single exposure to NBP induced more DNA damage in MCF7 cells than either NB
or PhIP (Figure 2.3A) indicating that NBP is more potent than either NB or PhIP alone to induce
DNA damage for cellular carcinogenesis, even in cancer cells. After five cycles of carcinogen
exposure, we detected significantly increased degrees of the cancer-associated properties of
RDGF (Figure 2.3B-1), AIG (2.3B-2), cell migration (2.3B-3), and invasion (2.3B-4) acquired
by carcinogen-exposed MCF7 cells versus parental cells. Although parental MCF7 cells
possessed levels of these cancer-associated properties comparable to levels in NBP20 and
MCF10A-Ras cells, these properties were significantly increased by NBP exposure, indicating
that cumulative exposures to NBP may increase the potency of already cancerous cells. NBP was
more potent than NB or PhIP in MCF7 cells, which is consistent with results seen in MCF10A
cells. We next investigated if cumulative exposures to NBP, NB, and PhIP also resulted in
induction of the biochemical endpoints of ROS elevation and Ras-ERK-Nox pathway activation
in MCF7 cells as they did in MCF10A cells. We detected that parental MCF7 cells possessed
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higher levels of ROS (Figure 2.3B-5), H-Ras expression, Erk1/2 activation, and Nox-1
expression (2.3B-6) than MCF10A cells, and cumulative exposures to NBP were able to
furthermore increase ROS production and Ras-ERK-Nox pathway induction in MCF7 cells.
Exposure to NBP resulted in higher levels of ROS production (Figure 2.3B-5) and Ras-ERKNox pathway induction (2.3B-6) in MCF7 cells than either NB or PhIP alone, consistent with the
higher levels of cancer-associated properties (2.3B-1 to 2.3B-4) acquired by NBP-exposed
versus NB- or PhIP-exposed MCF7 cells. Thus, these results lead us to suggest that cumulative
exposures to combined NNK, B[α]P, and PhIP were able to constitutively induce cellular
acquisition of cancer-associated properties and associated biochemical endpoints in not only
non-cancerous MCF10A cells, but also in cancerous MCF7 cells in a similar manner. A
combination of multiple carcinogens was more potent than individual carcinogens in long-term
induction of breast cell carcinogenesis. Thus, co-exposure to low doses of NNK, B[α]P, and
PhIP should be seriously considered in epidemiological studies to reveal the value of these
carcinogens in the development of sporadic breast cancer. Given their ability to increase cancerassociated properties in non-cancerous or cancerous cells alike, it is important to identify dietary
agents capable of blocking breast cell carcinogenesis induced by cumulative exposures to
combined carcinogens for early intervention of this disease.

Intervention of NBP-induced carcinogenesis
In our previous reports, we demonstrated that GTCs, at non-cytotoxic levels, were
capable of suppressing breast cell carcinogenesis induced by NB or PhIP [33–35]. EGCG, the
major catechin present in green tea extract, is the most commonly studied preventive GTC [44],
but some studies have shown that ECG may be more effective than EGCG in intervention of
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cellular carcinogenesis [34,45,46]. ECG and EGCG have similar molecular masses, 442.37 and
458.37 g/mol, respectively. Our previous studies revealed that both ECG and EGCG at 40 µg/mL
are toxic to MCF10A cells [34]. However, at a non-cytotoxic dose of 10 µg/mL, ECG is more
effective than EGCG in suppression of NB-induced cellular carcinogenesis [34]. ECG at 10
µg/mL and EGCG at 5 µg/mL show comparable effectiveness in suppression of PhIP-induced
cellular carcinogenesis [35]. Thus, to address whether ECG, EGCG, or a combination of both
would be most effective in suppressing NBP-induced cellular carcinogenesis, we initially studied
the effectiveness of ECG and EGCG, at non-cytotoxic doses, in blocking transient endpoints
induced by a single exposure to NBP and subsequently verified their ability to suppress NBPinduced constitutive endpoints after cumulative exposures.
As shown in Figure 2.4, both ECG (E) and EGCG (G), at 10 or 20 µg/mL, were able to
block NBP-induced transient endpoints of ROS elevation (2.4A-1) and DNA damage (2.4A-2),
with ECG being more effective than EGCG in suppressing these properties. Interestingly, a
combination of ECG and EGCG (E+G) at 5 or 10 µg/mL each was more effective than
individual catechins at 10 or 20 µg/mL, respectively, in suppression of NBP-induced ROS and
DNA damage, indicating that combined ECG and EGCG were optimal for blocking ROS
elevation and DNA damage induced by combined NNK, B[α]P, and PhIP. Consistently, ECG
was more effective than EGCG, and a combination of ECG and EGCG was more effective than
individual catechins in suppression of Ras expression, Erk1/2 activity, and Nox-1 expression
(Figure 2.4A-3), as well as cellular proliferation (2.4A-4) transiently induced by a single
exposure to NBP. These results indicate that a combination of ECG and EGCG, at non-cytotoxic
levels, was more effective than individual agents in blocking induction of breast cell
carcinogenesis by NBP.
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To verify the ability of ECG and EGCG to intervene with the progression of NBPinduced cellular carcinogenesis, we repeatedly exposed MCF10A cells to NBP in the absence or
presence of 20 µg/mL ECG (E), 20 µg/mL EGCG (G), or combined 10 µg/mL ECG and 10
µg/mL EGCG (E/G) for 10 cycles, resulting in the NBP10, NBP-E10, NBP-G10, and NBPE/G10 cell lines, respectively. In studies of the ability of ECG and/or EGCG to block NBPinduced cancer-associated properties, we detected that ECG was more effective than EGCG and
a combination of ECG and EGCG was more effective than individual catechins in intervention of
cellular acquisition of RDGF (Figure 2.4B-1), AIG (2.4B-2), increased cell migration (2.4B-3),
invasion (2.4B-4), and proliferation (2.4B-5), as well as ROS elevation (2.4B-6) and Ras-ERKNox pathway activation (2.4B-7). Furthermore, NBP-increased mammosphere formation (Figure
2.4B-8) and ALDH-positive stem-like cell population (2.4B-9) as well as EMT-associated
MMP-9 induction, Vimentin induction, EpCAM reduction, and E-cadherin reduction (2.4B-10)
were also blocked by co-exposure to ECG and EGCG. Consistently, ECG was more effective
than EGCG, and a combination of ECG and EGCG was more effective than individual catechins
in suppressing these properties. These results clearly indicate the effectiveness of ECG and
EGCG, at non-cytotoxic levels, in intervention of breast cell carcinogenesis associated with longterm exposure to NBP. A combination of ECG and EGCG was more effective than either agent
alone, at equivalent doses in intervention of NBP-induced breast cell carcinogenesis.
Our unique model presents several advantages over others to advance our understanding
of human breast carcinogenesis and early intervention. It is highly sensitive in detecting
physiologically-achievable, low doses of either weak or potent carcinogens capable of inducing
breast cell carcinogenesis. It takes a unique approach of exposing cells to carcinogens in a
cumulative manner for progressive induction of chronic carcinogenesis from non-cancerous to
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pre-cancerous and cancerous stages. In addition, it uses measurable transient and constitutive
cellular, biochemical, and molecular endpoints to determine the induction and progression of
cellular carcinogenesis and to identify non-cytotoxic agents effective in intervention. In this
communication, we used our model to demonstrate, for the first time, the ability of two relatively
weak breast carcinogens, NNK and B[α]P, to enhance breast cell carcinogenesis induced by
potent breast carcinogen PhIP; we also identified the ability of combined ECG and EGCG,
which was more effective than individual catechins, to intervene in carcinogenesis induced by
combined NNK, B[α]P, and PhIP. We reported that transient induction of ROS, the Ras-ERKNox pathway, cell proliferation, and DNA damage accounted for the mechanisms of initiation of
cellular carcinogenesis during each exposure to NNK, B[α]P, and/or PhIP [34,35], ultimately
leading to acquisition of cancer-associated properties and progression of cellular carcinogenesis
induced by cumulative exposures. These transient endpoints were highly enhanced by combined
NNK, B[α]P, and PhIP. Blockage of ROS elevation or the Ras-ERK-Nox pathway significantly
reduced NBP-induced DNA damage and cell proliferation, indicating essential roles of ROS
elevation and Ras-ERK-Nox pathway activation in NBP-induced cellular carcinogenesis.
Accordingly, transient induction of ROS elevation and the Ras-ERK-Nox pathway served not
only as markers for detecting NBP effects but also as targets for suppressing NBP-induced
carcinogenesis. As we demonstrated in this communication, we initially used ROS elevation and
the Ras-ERK-Nox pathway as targets to detect the optimal concentration and combination of
ECG and EGCG effective in suppression of NBP-induced transient endpoints. Subsequently, we
used cancer-associated properties/constitutive endpoints as targets to verify the effectiveness of
combined ECG and EGCG in intervention of NBP-induced progression of cellular
carcinogenesis. In addition, our model system is able to address whether preventive agents are
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effective in intervention of cancer stem-like cell development. Development of cancer stem-like
cells, involving induction of the EMT program, has been postulated to play important roles in
cancer development [37] and cancer recurrence after chemotherapy [47]. Using our model, we
demonstrated that combined ECG and EGCG was more effective than individual agents in
intervention of NBP-increased stem-like cell population and EMT program induction. Thus,
applying our model will accelerate our understanding of low-dose carcinogens in breast cell
carcinogenesis and identification of preventive agents effective in reducing the health risk of
sporadic breast cancer associated with chronic exposure to low doses of environmental and
dietary carcinogens.
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Figure 2.1. Enhanced cellular acquisition of cancer-associated properties by combined
carcinogens. (A) MCF10A cells were treated with combined 100 pmol/L NNK and 100 pmol/L
B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the absence and presence
of 10 µmol/L U0126 (U0) or 5 mmol/L NAC for 24 h. DNA damage was measured by a comet
assay and normalized by the value of average tail moment determined in untreated counterpart
cells, set as 1 (X, arbitrary unit). Representative images detected in the comet assay are shown.
(B-1 to B-6) MCF10A (10A) cells were repeatedly exposed to NB, PhIP, or NBP for 20 cycles,
resulting in the NB20, P20, and NBP20 cell lines, respectively. NB20 cells were then exposed to
PhIP for an additional 20 cycles resulting in the NB20/P20 cell line. MCF10A-Ras (Ras) cells
were used as a malignant control. (C-1 to C-3) NB20/P20 and NBP20 cells were treated with 10
µmol/L U0 or 5 mmol/L NAC for 48 h. (B-1) To determine cellular acquisition of RDGF, cells
were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted. (B2) To determine cellular acquisition of AIG, cells were seeded in soft agar for 14 days. Cell
colonies ≥0.1 mm diameter were counted. (B-3 and C-2) Relative level of ROS as fold induction
(X, arbitrary unit) was normalized by the level determined in untreated cells, set as 1. (B-4 and
C-3) Relative cell proliferation was determined and normalized by the value of BrdU detected in
untreated cells, set as 100%. B-5: Total RNA was isolated and analyzed by RT-PCR with
specific primers to determine relative gene expression levels of H-Ras, with β-actin as a control,
and these levels were quantified by densitometry. (B-6 and C-1) Cell lysates were analyzed by
immunoblotting using specific antibodies to detect levels of H-Ras, phosphorylated-Erk1/2 (pErk1/2), Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by
densitometry. The levels of H-Ras (Ras/actin) and Nox-1 (Nox/actin) were calculated by
normalizing with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary
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unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were calculated by normalizing the
levels of p-Erk1/2 with the levels of Erk1/2, then the level set in control cells as 1 (X, arbitrary
unit). Columns, mean of triplicates; bars, SD. All results are representative of three independent
experiments. Statistical significance is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 2.2. Enhanced acquisition of mesenchymal and stem-like cell properties by
combined carcinogens. (A) To determine cellular acquisition of the ability of serumindependent non-adherent growth (SINAG), MCF10A (10A), NB20, P20, NB20/P20, NBP20,
and MCF10A-Ras (Ras) cells were seeded in non-adherent cultures for 10 days; then,
mammospheres (≥0.1 mm diameter) were counted. (B) Mammospheres were collected and
trypsinized, and ALDH-expressing (ALDH+) cell population (%) was measured by flow
cytometry. (C) Cell lysates were analyzed by immunoblotting using specific antibodies to detect
levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin as a control, and these levels
were quantified by densitometry. The levels of EpCAM, E-cadherin, MMP-9, and Vimentin
were calculated by normalizing with the level of β-actin and the level set in untreated control
cells as 1 (X, arbitrary unit). (D) Cellular migratory and E: invasive activities were determined
by counting the numbers of cells translocated through a polycarbonate filter without or with
coated Matrigel, respectively, in 10 arbitrary visual fields. (F-1) Cellular acquisition of increased
motility was determined by wound healing assay. The wounded areas were examined
(magnification, 100×) 6, 12, and 24 h afterward. Arrows indicate width of wounded areas. (F-2)
To quantitatively measure cell motility detected in F-1, the area not healed by the cells was
subtracted from the total area of the initial wound to calculate the wound healing area (%) at
intervals of 6 (white columns) and 12 h (gray columns). Columns, mean of triplicates; bars, SD.
All results are representative of three independent experiments. Statistical significance is
indicated by * P<0.05, ** P<0.01, and *** P<0.001.

131

Figure 2.2
Enhanced acquisition of mesenchymal and stem-like cell properties by combined
carcinogens

132

Figure 2.2
Enhanced acquisition of mesenchymal and stem-like cell properties by combined
carcinogens
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Figure 2.3. NBP-enhanced cancer-associated properties in breast cancer MCF7 cells. (A)
MCF10A cells (10A) were treated with NBP, and MCF7 cells were treated with NBP, NB, or
PhIP (P) for 24 h. DNA damage was measured by a comet assay and normalized by the value of
average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (B-1 to
B-6) MCF7 cells were exposed to NBP, NB, or PhIP for five cycles (NBP5, NB5, and P5). The
NBP20 and MCF10A-Ras (Ras) cell lines were used as comparisons. (B-1) To determine cellular
acquisition of RDGF, cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm
diameter were counted. (B-2) To determine cellular acquisition of AIG, cells were seeded in soft
agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. Cellular migratory (B-3) and
invasive (B-4) activities were determined by counting the numbers of cells translocated through
a polycarbonate filter without or with coated Matrigel, respectively, in 10 arbitrary visual fields.
(B-5) Relative level of ROS as fold induction (X, arbitrary unit) was normalized by the level
determined in untreated cells, set as 1. (B-6) Cell lysates were analyzed by immunoblotting using
specific antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a
control, and these levels were quantified by densitometry. Levels of H-Ras (Ras/actin) and Nox1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the
level set in control cells as 1 (X, arbitrary unit). Columns, mean of triplicates; bars, SD. All
results are representative of three independent experiments. Statistical significance is indicated
by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 2.4. Intervention of NBP-induced carcinogenesis. (A-1 to A-4) MCF10A cells were
treated with NBP in the absence and presence of ECG (E), EGCG (G), or a combination of ECG
and EGCG (E+G) for 24 hr. (B-1 to B-10) MCF10A (10A) cells were exposed to NBP in the
absence and presence of 20 µg/mL ECG, 20 µg/mL EGCG, or combined 10 µg/mL ECG and 10
µg/mL EGCG (E/G) for 10 cycles, resulting in the NBP10, NBP-E10, NBP-G10, and NBPE/G10 cell lines, respectively. (A-1 and B-6) Relative level of ROS as fold induction (X,
arbitrary unit) was normalized by the level determined in untreated cells, set as 1. (A-2) Relative
DNA damage was measured by a comet assay and normalized by the value of average tail
moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (A-3 and B-7) Cell
lysates were analyzed by immunoblotting using specific antibodies to detect levels of H-Ras,
phosphorylated-Erk (p-Erk), Erk, and Nox-1, with β-actin as a control, and these levels were
quantified by densitometry. Levels of H-Ras and Nox-1 were calculated by normalizing with the
level of β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). Levels of
specific phosphorylation of Erk (p/Erk) were calculated by normalizing the levels of p-Erk with
the levels of Erk, then the level set in control cells as 1 (X, arbitrary unit). (A-4 and B-5) Relative
cell proliferation was determined and normalized by the value of BrdU detected in untreated
cells, set as 100%. (B-1) To determine cellular acquisition of RDGF, cells were maintained in
LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted. (B-2) To determine
cellular acquisition of AIG, cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm
diameter were counted. (B-3) Cellular migratory and (B-4) invasive activities were determined
by counting the numbers of cells translocated through a polycarbonate filter without or with
coated Matrigel, respectively, in 10 arbitrary visual fields. (B-8) To determine cellular
acquisition of the ability of serum-independent non-adherent growth (SINAG), cells were seeded
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in non-adherent cultures for 10 days; then, mammospheres (≥0.1 mm diameter) were counted.
(B-9) Mammospheres were collected and trypsinized, and ALDH-expressing (ALDH+) cell
population (%) was measured by flow cytometry. (B-10) Cell lysates were analyzed by
immunoblotting using specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and
Vimentin, with β-actin as a control, and these levels were quantified by densitometry. The levels
of EpCAM, E-cadherin, MMP-9 and Vimentin were calculated by normalizing with the level of
β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). Columns, mean of
triplicates; bars, SD. All results are representative of three independent experiments. Statistical
significance is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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CHAPTER 3

Reactive oxygen species-mediated breast cell carcinogenesis enhanced by
multiple carcinogens and intervened by dietary ergosterol and mimosine
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Research described in this chapter is a slightly modified version of an article that has been
submitted for publication in Free Radical Biology and Medicine by Lenora Ann Pluchino,
Amethyst Kar-Yin Liu and Hwa-Chain Robert Wang

Lenora Ann Pluchino, Amethyst Kar-Yin Liu and Hwa-Chain Robert Wang. Reactive oxygen
species-mediated breast cell carcinogenesis enhanced by multiple carcinogens and intervened by
dietary ergosterol and mimosine. (Free Radical Biology and Medicine, Submitted June 2014).

In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing
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Abstract
Most breast cancers occur sporadically due to long-term exposure to low doses of
carcinogens present in the polluted environment and diet. American lifestyles involve frequent
exposures to smoke, polluted air and high temperature-cooked meats comprising multiple
carcinogens, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[α]pyrene
(B[α]P), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). However, whether
these carcinogens may act together to enhance breast cell carcinogenesis is unclear. Here, we
demonstrate that co-exposure to physiologically-achievable doses of NNK, B[α]P, and PhIP
(NBP) holistically enhanced initiation and progression of breast cell carcinogenesis. Reactive
oxygen species (ROS) and ERK pathway activation were transiently induced by each NBP
exposure, and cross-talk between reinforced ROS elevation and ERK activation played an
essential role in increased DNA oxidation and damage. After cumulative NBP exposures, this
cross-talk contributed to enhanced initiation of cellular carcinogenesis and led to enhanced
acquisition of cancer-associated properties. Using NBP-induced transient changes, such as ROS
elevation and ERK pathway activation, and cancer-associated properties as targeted endpoints,
we revealed, for the first time, that two less-studied dietary compounds, ergosterol and
mimosine, at biologically-achievable non-cytotoxic levels, were highly effective in suppressing
NBP-induced cellular carcinogenesis. Combined ergosterol and mimosine was more effective
than individual agents in blocking NBP-induced transient endpoints, including ROS-mediated
DNA oxidation, which accounted for its ability to suppress progression of NBP-induced cellular
carcinogenesis. Thus, dietary components such as mushrooms containing ergosterol and legumes
containing mimosine should be considered for affordable prevention of sporadic breast cancer
associated with chronic exposure to environmental and dietary carcinogens.
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Introduction
Breast cancer is the most common type of cancer and second-leading cause of cancerrelated death among North American and European women [1]. Most breast cancers occur
sporadically due to chronic exposure to multiple environmental carcinogens in a multi-step
process that results in the transformation of breast cells from a non-cancerous stage to precancerous and cancerous stages [2,3]. We have developed a chronically-induced breast cell
carcinogenesis model to mimic sporadic breast cancer development associated with long-term
exposure to low doses of carcinogens [4-9]. In this model, we repeatedly expose immortalized,
non-cancerous, human breast epithelial cells to physiologically-achievable doses of carcinogens
to progressively induce cellular acquisition of various cancer-associated properties for studies to
reveal cellular, biochemical, and molecular changes. Then, we use these changes as targeted
endpoints to identify preventive agents capable of intervening in cellular carcinogenesis [4-9].
The mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is
the most abundant heterocyclic amine produced in high-temperature cooked meat, and
circulating plasma levels of PhIP can reach nanomolar levels in humans following cooked meat
consumption [10]. In rats, gastric administration of PhIP induces mammary tumors [11]. In
addition, epidemiological studies have indicated a close association between well-done meat
consumption and human breast cancer risk [12,13]. The tobacco-specific nitrosamine ketone 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is widely accepted as a lung carcinogen
and can be detected at picomolar concentrations in the body fluids of tobacco users [14]. Despite
evidence that gastric administration into rats resulted in mammary tumor development [15],
NNK is not recognized as a mammary carcinogen. Although the link between smoking and
breast cancer is controversial, recent studies have indicated that exposure to tobacco smoke can
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increase breast cancer risk, especially in post-menopausal women [16,17]. Benzo[α]pyrene
(B[α]P) is a polycyclic aromatic hydrocarbon in smoke produced from the incomplete
combustion of organic materials, such as fossil fuels and tobacco [18]. B[α]P can be found at
picomolar concentrations in human fat and liver [19] and is classified as a weak mammary
carcinogen in humans [18,20,21]. American lifestyles involve frequent consumption of hightemperature cooked meats containing carcinogens such as PhIP and wide exposures to smoke
and polluted air containing NNK and B[α]P. However, whether these carcinogens may act
together to cause breast cell carcinogenesis needs to be verified.
Epidemiological and experimental evidence suggests that certain dietary compounds
possess anticancer activities [3]. Ergosterol is a sterol that forms the major constituent of the
fungal cell membrane [22]. Common dietary sources include mushrooms, morels, and truffles
[22], as well as products made with yeasts such as soy sauce, bread, and beer [23-25]. Studies
showed that ergosterol at micro-molar levels is cytotoxic against human breast cancer cell lines
and a variety of other tumor cell lines [26,27]. In vivo studies identified ergosterol as a
protective agent against the promotion of carcinogen-induced bladder tumors in rats [28] and
tumor promotion in mice [29]. Mimosine is an alkaloid, non-proteinogenic amino acid found
exclusively in tropical legumes of the Mimosa and Leucaena genera [30]. Mimosine is an iron
chelator that inhibits DNA synthesis and causes cell cycle arrest in late G1 phase [30]. Studies
showed that micro-molar levels of mimosine inhibit proliferation of breast, lung, and ovarian
cancer cell lines [31-33], and mimosine is effective in reducing xenograft development of human
lung and pancreatic carcinoma cells by increasing the apoptotic index of cancer cells [34,35].
Although much research has focused on the use of high doses of ergosterol and mimosine to
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inhibit growth or induce apoptosis of cancer cells, little work has been undertaken to evaluate the
ability of these agents, at non-cytotoxic levels, to prevent cellular carcinogenesis.
Given the ubiquitous nature of tobacco smoke, carbon exhaust, and cooked meat in
modern societies, it is important to holistically examine the role of carcinogens, such as NNK,
B[α]P, and PhIP, in induction of breast cell carcinogenesis to reveal associated mechanisms and
targeted endpoints for intervention. Previously, we used our breast cell carcinogenesis model
system to demonstrate the ability of NNK at100 pmol/L, B[α]P at 100 pmol/L, and PhIP at 10
nmol/L to individually induce initiation and progression of breast cell carcinogenesis [4,5,9].
NNK and B[α]P exhibited comparable abilities to induce cellular carcinogenesis, and combining
NNK and B[α]P (NB) additively increased degrees of acquired cancer-associated properties,
such as reduced dependence on growth factors and anchorage-independent growth, as well as
stem-like cell- and epithelial-to-mesenchymal transition (EMT)-associated properties [6-9].
These measurable cancer-associated properties, acquired by cells after cumulative exposures to
carcinogens, represent constitutive endpoints to reveal stages in the progress of cellular
carcinogenesis from non-cancerous to premalignant and malignant stages. Using our model, we
have also identified endpoints that are transiently induced by a single carcinogen exposure, such
as DNA damage and increased cell proliferation, which play essential roles in induction of
carcinogenesis and account for the mechanisms of initiation of cellular carcinogenesis during
each carcinogen exposure [6,7,9]. Our model system enables us to develop a two-step strategy
by also using these transient and constitutive endpoints as targets to identify preventive agents
capable of blocking cellular carcinogenesis [5-9].
Herein, we describe use of our model system to elucidate the ability, and associated
mechanisms, of NB to enhance PhIP-induced cellular carcinogenesis. We also used our model
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as a target system to demonstrate, for the first time, the ability, and associated mechanisms, of
ergosterol and mimosine individually and in combination to suppress cellular carcinogenesis
induced by combined NNK, B[α]P, and PhIP.

Materials and Methods
Cell cultures and reagents
MCF10A, MCF12A (American Type Culture Collection [ATCC], Rockville, MD) and
derived cell lines were maintained in complete medium (CM) (1:1 DMEM/HAM's F12, 100
ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol, 20 ng/mL epidermal
growth factor, and 5% horse serum) [4-9]. All cultures were supplemented with 100 U/mL
penicillin and 100 µg/mL streptomycin and maintained in 5% CO2 at 37°C. Stock solutions of
NNK (Chemsyn, Lenexa, KS), B[α]P (Aldrich, Milwaukee, WI), PhIP (Midwest; NCI Chemical
Carcinogen Reference Standard Repository), U0126 (Cell Signaling, Beverly, MA), and CMH2DCF-DA (Invitrogen, Carlsbad, CA) were prepared in DMSO; ergosterol (Sigma-Aldrich, St.
Louis, MO) was prepared in chloroform; N-acetyl-L-cysteine (NAC) (Alexis, San Diego, CA)
was prepared in distilled water, and mimosine (Sigma-Aldrich) was prepared in distilled water
with 10% NaOH. All were diluted in CM for assays.

Chronic induction of cellular carcinogenesis
Twenty-four hours after subculturing, human breast cells were treated with the indicated
carcinogens and/or preventive agents for 48 h as one cycle of exposure for 5-20 cycles. Cells
were subcultured every 3 days [4-9].
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Cell viability
A methyl thiazolyl tetrazolium (MTT) assay kit (ATCC) was used to measure cell
viability. A total of 5×103 cells/well in 96-well culture plates were incubated with MTT reagent
for 4 h, followed by incubation with detergent reagent for 24 h. Reduced MTT reagent in
cultures was quantified with an ELISA reader (Bio-Tek) at 570 nm.

Reduced dependence on growth factors
A total of 5×103 cells were seeded in 60-mm culture dishes and maintained in lowmitogen (LM) medium (1:1 DMEM/F12, 2 ng/mL cholera enterotoxin, 200 ng/mL insulin, 10
ng/mL hydrocortisol, 0.4 ng/mL epidermal growth factor, and 0.1% horse serum), containing
reduced total serum and mitogenic additives to 2% of the concentration formulated in CM, for 10
days to develop cell colonies [4-9].

Anchorage-independent growth
A total of 1×104 cells were mixed with soft agar consisting of 0.4% low-melting agarose
(Fisher, Fair Lawn, NJ) in a mixture (1:1) of CM with 3-day conditioned medium prepared from
MCF10A cultures, plated on top of a 2% low-melting agarose base layer in 60-mm culture dishes
and maintained for 14 days to develop cell colonies [4-9].
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Cell proliferation
Cell proliferation was determined using the 5-bromo-2-deoxyuridine (BrdU) cell
proliferation enzyme-linked immunosorbent assay (ELISA) kit (Roche, Indianapolis, IN); BrdUlabeled cells were quantified using an ELISA reader (Bio-Tek, Winooski, VT), as described
previously [4-9].

Serum-independent non-adherent growth
A total of 1×104 cells were seeded on top of 1% agarose-coated, non-adherent 100-mm
culture plates, incubated in serum-free CM supplemented with 0.4% bovine serum albumin and
maintained for 10 days to develop mammospheres [8,9].

Aldehyde dehydrogenase (ALDH)
An ALDEFLUOR Kit (StemCell Technologies, Durham, NC) was used to detect ALDHexpressing cells by flow cytometry, as described previously [8.9]. Mean fluorescence intensity of
cells was quantified using Multicycle software (Phoenix Flow System). Cells incubated with
activated Aldefluor substrate BODIPY-aminoacetaldehyde (BAAA) in the presence of the
ALDH inhibitor diethylaminobenzaldehyde (DEAB) were used to establish the baseline of
fluorescence for determining the ALDH-expressing cell population (%) in which ALDH activity
was not inhibited by DEAB.
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In vitro cell invasion and migration
The in vitro cell invasion assay was performed using 24-well transwell insert chambers
with an 8.0 µm pore size polycarbonate filter (Costar, Corning, NY). A total of 2×104 cells in
serum-free CM were seeded on top of a Matrigel-coated filter (BD Biosciences, Franklin Lakes,
NJ) in each insert chamber. Insert chambers were then placed into wells on top of culture
medium containing 10% horse serum as a chemoattractant. The in vitro migration assay was
performed using 24-well Transwell insert chambers with a polycarbonate filter not coated in
Matrigel. After 24 h, the migratory and invasive ability of cells was determined by the number of
cells translocated to the lower side of filters [8,9].

Cell motility wound-healing
Cells were seeded in 6-well plates, grown to confluence in CM, rinsed with PBS and
serum-starved for 15 h in DMEM/Ham’s F12 medium containing 2% horse serum. The
monolayer was scratched with a 23-gauge needle (BD Biosciences) to generate wounds, rinsed
with CM to remove floating cells, and then maintained in CM. The wounded areas were
examined 6, 12 and 24 h after scratches to detect healing. The area not healed by the cells was
subtracted from the total initial wound area to calculate the wound healing area at time intervals
of 6 and 12 h, using Total Lab TL100 software (Total Lab, Newcastle, NE) [7,8].

Intracellular ROS
Cells were labeled with 5 µmol/L chloromethyl-dichlorodihydrofluorescein-diacetate
(CM-H2DCF-DA) for 1 h to detect ROS by flow cytometry as described previously [4-9]. Mean
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fluorescence intensity of dichlorodihydrofluorescein (DCF) was quantified using Multicycle
software (Phoenix Flow System, San Diego, CA).

DNA damage
DNA damage was detected using the comet assay [38]. A total of 2×104 cells in cold
phosphate-buffered saline (PBS) were mixed with 1% low-melting agarose (Fisher) and placed
on agarose-coated slides. Slides were immersed in alkaline lysis solution (pH 13) at 25º C for 1
h, rinsed with alkaline buffer (pH>13), electrophoresed in the same buffer at 20 V for 30 min,
stained with propidium iodide and examined with a fluorescence microscope (Carl Zeiss Inc.,
Thornwood, NY), as described previously [4-9]. Fifty nuclei per slide were scored for tail
moment (% DNA in the tail × tail length) using CometScore software (Tritek, Sumerduck, VA).

DNA oxidation
DNA oxidation was detected using a modified comet assay [39]. In brief, after seeding
cells onto agarose-coated slides, slides were immersed in neutral lysis solution (2.5 mol/L NaCl,
0.1 mol/L Na2-EDTA and 10 mmol/L Tris, pH 8) and incubated with enzyme reaction buffer (40
mmol/L HEPES, 0.1 mol/L KCl, 0.5 mmol/L Na2-EDTA and 0.2 mg/mL BSA, pH 8) buffer with
and without formamidopyrimidine (fapy)-DNA glycosylase (Fpg) enzyme. Slides were then
placed in alkaline buffer, electrophoresed in alkaline buffer, rinsed with neutralization buffer (0.4
mol/L Tris, pH 7.5), stained with propidium iodide, and examined with a fluorescence
microscope, as described above.
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Reverse-transcription PCR
Total RNA isolated from cultures using the Absolutely RNA kit (Stratagene, La Jolla,
CA) was reverse transcribed to complementary DNA using the Verso cDNA Kit (Thermo
Scientific, Waltham, MA). The resulting cDNAs were subjected to PCR for H-Ras (forward: 5’GACGGAATATAAGCTGGTGG-3’; reverse: 5’-AGGCACGTCTCCCCATCAAT-3’) and βactin (forward: 5’-GGACTTCGAGCAAGAGATGG-3’; reverse: 5’AGCACTGTGTTGGCGTACG-3’). PCR products were electrophoresed on agarose gels and
visualized using ethidium bromide staining.

Immunoblotting
Cell lysates were prepared and protein concentrations were measured using the BCA
assay (Pierce, Rockford, IL), as described previously [4-9]. Equal amounts of cellular proteins
were resolved by electrophoresis in 8%, 10% or 12% sodium dodecyl sulfate-polyacrylamide
gels and transferred to nitrocellulose membranes for immunoblotting, using specific antibodies to
detect H-Ras, Raf-1, phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, EpCAM, E-cadherin,
MMP-9, Vimentin, β-actin (Santa Cruz Biotechnology, Santa Cruz, CA), p-Raf-1, p-Mek1/2 and
Mek1/2 (Cell Signaling). Antigen-antibody complexes on membraness were detected by the
Supersignal chemiluminescence kit (Pierce).
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Statistical analysis
The Student t test was used to analyze statistical significance, indicated by * P<0.05,
**P<0.01, and *** P<0.001; a P value <0.05 was considered significant.

Results
Exposure-dependent enhancement of cancer-associated properties by combined
carcinogens
To investigate the ability of combined NNK and B[α]P (NB) to enhance PhIP-induced
breast cell carcinogenesis, we repeatedly exposed MCF10A cells to PhIP in the absence and
presence of NB for 5, 10, 15, and 20 cycles. Then, we measured the degrees of two acquired
cancer-associated properties to assess the progression of cellular carcinogenesis. Growth factors
and cellular adhesion to the extracellular matrix are required for normal epithelial cell survival;
in contrast, cancerous cells acquire a reduced dependence on growth factors (RDGF) and
anchorage-independent growth (AIG) to increase aberrant survival [40]. As shown in Figures
3.1A-1 and 3.1A-2, cumulative exposures to individual or combined NB and PhIP resulted in
increasing acquisition of RDGF and AIG in an exposure-dependent manner. NB and PhIP
exhibited comparable abilities to induce cellular acquisition of these cancer-associated
properties; combined NB and PhIP (NBP) exhibited significantly higher abilities than individual
agents to increase acquisition of these properties.
To further understand the exposure-dependent nature of NBP-induced carcinogenesis, we
established MCF10A-NBP5, -NBP10, -NBP15, and -NBP20 cell lines resulting from repeated
exposures of MCF10A cells to NBP for 5, 10, 15, and 20 cycles, respectively. We investigated
152

additional cancer-associated properties acquired by these NBP-induced cell lines and used the
MCF10A-Ras cell line [41], in which oncogenic H-Ras is ectopically expressed in MCF10A
cells, as a malignant control. ROS elevation and increased cell proliferation are closely
associated with cellular transformation [40]. As shown in Figures 3.1B-1 and 3.1B-2,
cumulative exposure to NBP resulted in increased ROS elevation and cell proliferation in these
cell lines in an exposure-dependent manner. Upregulation of the Ras-ERK pathway contributes
to increased cell proliferation and leads to expression of NADPH oxidase-1 (Nox-1), which
mediates non-mitochondrial production of ROS [42]. We detected that H-Ras gene expression
was increasingly upregulated by cumulative exposures to NBP (Figure 3.1B-3); H-Ras protein
level, phosphorylation of downstream kinases Raf-1, Mek1/2, and Erk1/2, as well as Nox-1
expression were accordingly upregulated in these cells (3.1B-4). These results indicate that the
Ras-ERK-Nox pathway was activated in concert with progression of NBP-induced breast cell
carcinogenesis.
Stem-like cells and the EMT program play important roles in various stages of cancer
development [40]. Our previous studies suggested that acquisition of stem-like cell- and EMTassociated properties is associated with breast cell carcinogenesis [8,9]. Mammary stem-like
cells have a unique ability to form discrete non-adherent mammospheres and have high levels of
aldehyde dehydrogenase (ALDH) activity [43,44]. As shown in Figures 3.1B-5 and 3.1B-6, both
the number of mammospheres and the population of ALDH-positive cells were progressively
increased by cumulative exposures to NBP. The ability to develop stem-like cells is associated
with activation of the EMT program, which confers cells with mesenchymal properties such as
increased migration and invasion [40]. As shown in Figure 3.1B-7, the epithelial cell markers
EpCAM and E-cadherin and the EMT markers MMP-9 and Vimentin were reduced and
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increased, respectively, in concert with NBP-induced cellular carcinogenesis and increased stemlike cell populations. In addition, the EMT-associated properties of cell migration (3.1B-8) and
invasion (3.1B-9) were also accordingly increased. These results, taken together, indicate that
cumulative exposures to physiologically-achievable doses of NB and PhIP in combination were
able to enhance cellular acquisition of cancer-associated properties, including stem-like and
mesenchymal cell properties, in an exposure-dependent manner.

Enhanced initiation of cellular carcinogenesis by combined carcinogens
To investigate the mechanisms of NB in enhancing PhIP-induced cellular carcinogenesis,
we studied the ability of NB, PhIP, and NBP to induce transient endpoints that are essential for
induction of cellular carcinogenesis in a single exposure [7,9]. We detected that a single NBP
exposure induced higher levels of DNA damage (Figure 3.2A-1), ROS elevation (3.2A-2), cell
proliferation (3.2A-3), Ras gene upregulation (3.2A-4), Ras-ERK activation, and Nox-1
upregulation (3.2A-5) than either NB or PhIP. These results indicate that co-exposure to NB
enhanced the ability of PhIP to induce these transient endpoints. It has been reported that ROS
elevation may lead to activation of the ERK pathway, and activation of the ERK-Nox pathway
induces ROS elevation [42,45,46]. To elucidate whether ROS elevation and the ERK-Nox
pathway interplayed during NB-, PhIP-, and NBP-initiated cellular carcinogenesis, we studied
the time course of ROS elevation and ERK pathway activation. We detected that NB, PhIP, and
NBP induced distinct profiles of ROS elevation (Figure 3.2B-1 & 3.2B-2) and ERK pathway
activation (3.2C-1 & 3.2C-2). NBP exposure promptly induced ROS to maximal levels in 6 hr,
while NB and PhIP progressively induced ROS to maximal levels in 12 and 24 hr, respectively;
NBP induced significantly higher levels of ROS than NB or PhIP (3.2B-1 & 3.2B-2). These
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carcinogens induced ERK activation reaching maximal levels by 24 hr; however, NBP induced
higher degrees of ERK activation than either NB or PhIP (3.2C-1 & 3.2C-2). These results
indicate that NB and NBP induced ROS elevation prior to ERK pathway activation, and PhIP
induced ROS elevation and ERK activation in parallel; both Nox-dependent and -independent
ROS elevations were involved in initiation of cellular carcinogenesis by NB, PhIP, and NBP.
Co-exposure to NB not only significantly increased but also accelerated PhIP-induced ROS
elevation and ERK pathway activation. These data suggest that ROS elevation and the ERKNox pathway may interplay during initiation of cellular carcinogenesis.

ROS and the Ras-ERK pathway in initiation and maintenance of cellular carcinogenesis
To address whether ROS elevation cross-talked with the ERK pathway, we used the
Mek1/2 inhibitor U0126 to block ERK pathway (Figure 3.3A-1) and the general antioxidant Nacetyl-L-cysteine (NAC) to block ROS (3.3A-2). Treatment with U0126 blocked NB-, PhIP-,
and NBP-induced ERK activation and Nox-1 elevation, but did not significantly affect H-Ras
expression (3.3A-1). U0126 treatment failed to reduce NB-induced ROS elevation but
significantly reduced PhIP- and NBP-induced ROS (3.3A-2), indicating the role of ERK
activation in ROS elevation induced by PhIP and NBP, but not NB. NAC treatment reduced
NB-, PhIP-, and NBP-induced H-Ras expression, ERK activation, and Nox-1 elevation (3.3A-1),
indicating the role of ROS elevation in activation of the Ras-ERK-Nox pathway by all these
carcinogens. Accordingly, ROS elevation and the ERK pathway mutually interplayed in the
initiation of cellular carcinogenesis induced by PhIP or NBP; in contrast, ROS elevation led to
ERK activation during NB-initiated carcinogenesis. Blockage of either ROS elevation or ERK
pathway activation significantly suppressed cell proliferation and DNA damage induced by all
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these carcinogens (Figure 3.3A-3 & 3.3A-4), indicating that ROS elevation and ERK pathway
activation were essential for increased cell proliferation and DNA damage during the initiation of
cellular carcinogenesis by NB, PhIP, and NBP. However, how ROS elevation results in ERK
pathway activation by NB remains to be investigated.
To validate the roles of ROS elevation and ERK pathway activation in the progression of
cellular carcinogenesis, we repeatedly exposed MCF10A cells to NB, PhIP, or NBP in the
absence and presence of U0126 or NAC for 10 cycles. Blockage of either the ERK pathway or
ROS elevation in each cycle resulted in significant suppression of cellular acquisition of RDGF,
AIG, cell migration, and invasion after accumulated exposures (Figures 3.3B-1 to 3.3B-4).
These results indicate that inhibition of either the ERK pathway or ROS elevation in each
exposure cycle effectively blocked progression of carcinogenesis induced by cumulative
exposures to carcinogens.

Ergosterol and mimosine intervened in cellular carcinogenesis
Co-exposure to NB was able to significantly enhance PhIP’s ability to induce cellular
carcinogenesis. Identifying dietary agents effective in intervention of NBP-induced cellular
carcinogenesis is an affordable option for prevention of breast cancer. Considering the toxicity
resulting from long-term use of anticancer agents, use of dietary agents at non-cytotoxic levels
should be adopted as the key strategy for cancer prevention. In searching for optimal dietary
agents, we detected that ergosterol and mimosine were effective in suppressing NBP-induced
cellular carcinogenesis. Initially, by measuring the effects of various concentrations of
ergosterol and mimosine individually on MCF10A cell viability, we determined the noncytotoxic concentrations of ergosterol at ≤1 µmol/L and mimosine at ≤5 µmol/L (Figures 3.4A-1
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to 3.4A-2). Subsequently, we determined that a combination of ≤0.5 µmol/L ergosterol and ≤0.5
µmol/L mimosine was not cytotoxic to MCF10A cells (Figure 3.4A-3). Studies indicated
physiologically-achievable doses of ergosterol and mimosine at nano-molar levels [36,37].
Accordingly, we used 10 nmol/L ergosterol, 10 nmol/L mimosine, and combined 5 nmol/L
ergosterol and 5 nmol/L mimosine to determine their ability to intervene in NBP-induced cellular
carcinogenesis. Using NBP-induced transient endpoints as targets, we detected that ergosterol or
mimosine was able to suppress NBP-induced DNA damage (Figure 3.5A-1), ROS elevation
(3.5A-2), cell proliferation (3.5A-3), and Ras-ERK-Nox pathway activation (3.5A-4); a
combination of ergosterol and mimosine completely blocked these NBP-induced transient
endpoints. To validate the ability of ergosterol and mimosine to intervene with progression of
carcinogenesis induced by cumulative exposures to NBP, we repeatedly exposed MCF10A cells
to NBP in the absence and presence of ergosterol and mimosine individually and in combination
for 10 cycles. Exposure to either ergosterol or mimosine simultaneously with NBP significantly
reduced cellular acquisition of RDGF (Figure 3.5B-1), AIG (3.5B-2), ROS elevation (3.5B-3),
increased cell proliferation (3.5B-4), and Ras-ERK-Nox pathway activation (3.5B-5). Exposure
to either ergosterol or mimosine also significantly reduced mammosphere formation (3.5B-6),
ALDH-positive cell population (3.5B-7), and the EMT-associated markers MMP-9 and Vimentin
(3.5B-8), as well as decreased the EMT- and cancer-associated properties of cell migration
(3.5B-9), invasion (3.5B-10), and motility (3.5C-1 & 3.5C-2). Combined ergosterol and
mimosine was more effective than either agent in suppressing these properties and appeared to
completely suppress cellular acquisition of all cancer-associated properties (3.5B-1 to 3.5B-10,
3.5C-1 & 3.5C-2). Thus, ergosterol plus mimosine appeared to be the optimal combination for
intervention of cellular carcinogenesis induced by long-term exposure to NBP.
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Ergosterol and mimosine suppressed oxidative DNA damage induced by carcinogens
DNA damage, resulting from ROS-mediated oxidation, is an underlying cause of cellular
carcinogenesis [40,47]. ROS elevation was essential for initiation of NBP-induced cellular
carcinogenesis. To further understand if ROS-mediated oxidation of DNA was involved in DNA
damage induced by carcinogens, we used the repair endonuclease Fpg. Fpg removes oxidized
DNA bases to cause broken strands that are detectable with a modified comet assay [39]. We
detected that DNA oxidation was induced in concert with DNA damage induced by NNK,
B[α]P, NB, PhIP, and NBP (Figure 3.6A-1 & 3.6A-2); blockage of ROS elevation by NAC
suppressed DNA oxidation (3.6B-1 & 3.6B-2), indicating that ROS-mediated oxidation of DNA
was involved in carcinogen-induced DNA damage.
Both ergosterol and mimosine were able to reduce NBP-induced ROS elevation and
DNA damage. To determine if ergosterol and mimosine were able to block carcinogen-induced
DNA oxidation, we treated cells with carcinogens in the absence and presence of ergosterol
and/or mimosine. We detected that combined ergosterol and mimosine was more effective than
individual agents in suppression of DNA damage, ROS elevation, and DNA oxidation induced
by carcinogens (Figures 3.6C-1 to 3.6C-3). These results indicate the antioxidant ability of
ergosterol and mimosine to protect chromosomal DNA from oxidative damage in cells during
exposure to NNK, B[α]P, and PhIP.

Induction of cellular carcinogenesis in MCF12A cells and suppression by ergosterol and
mimosine
To investigate whether the ability of NB to enhance PhIP-induced cellular carcinogenesis
and the effectiveness of ergosterol and mimosine in intervention of breast cell carcinogenesis
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were limited to the estrogen receptor (ER)-negative MCF10A cell line, we performed studies on
the non-cancerous human breast epithelial ER-positive MCF12A cell line, which is unrelated to
MCF10A cells. Based on the results of non-cytotoxic concentrations of ergosterol and mimosine
on MCF12A cells (Figures 3.4B-1 to 3.4B-3), we again used 10 nmol/L ergosterol, 10 nmol/L
mimosine, and combined 5 nmol/L ergosterol and 5 nmol/L mimosine. Consistently, NB coexposure enhanced PhIP-induced transient endpoints of DNA damage, ROS elevation, cell
proliferation, and Ras-ERK-Nox pathway in MCF12A cells in a single cycle and combined
ergosterol and mimosine were more effective than individual agents in suppression of these
transient endpoints (Figures 3.7A-1 to 3.7A-4). After 20 cycles of exposure, we detected that
cells exposed to NBP acquired significantly higher degrees of all the measured cancer-associated
properties than cells exposed to either NB or PhIP; these cancer-associated properties included
RDGF, AIG, ROS elevation, increased cell proliferation, Ras-ERK-Nox pathway activation,
mammosphere formation, enriched stem-like cell population, EMT markers, cell migration, and
cell invasion (Figures 3.7B-1 to 3.7B-10). To verify the ability of ergosterol and mimosine to
intervene in NBP-induced cancer-associated properties, we repeatedly exposed MCF12A cells to
NBP in the absence and presence of ergosterol and mimosine individually and in combination for
10 cycles. We detected that combined ergosterol and mimosine was more effective than either
agent in suppressing NBP-induced cancer-associated properties, and combined ergosterol and
mimosine completely suppressed cellular acquisition of cancer-associated properties induced by
cumulative exposures to NBP (Figures 3.7B-1 to 3.7B-10). Thus, the ability of co-exposure to
NB to enhance PhIP-induced cellular carcinogenesis and the ability of ergosterol and mimosine
to intervene in breast cell carcinogenesis were not cell line-dependent.
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Discussion
In this communication, we demonstrated that cumulative co-exposures to
physiologically-achievable levels of multiple environmental and dietary carcinogens resulted in
enhanced breast cell carcinogenesis. Nano-molar PhIP and pico-molar NNK and B[α]P are
physiologically achievable in the human body [10,14,19]. Our model system permits a highly
relevant approach to determine mechanisms involved in the development of sporadic breast
cancer associated with long-term exposure to low doses of carcinogens existing in our
environment and diets. The findings then can be used as targets for identifying preventive agents
effective in intervention of cancer development.
ROS elevation and ERK pathway activation appeared to play key roles in NBP-induced
cellular carcinogenesis. NB and PhIP induced distinct elevation kinetics of ROS, and NBexposed cells reached maximal ROS level earlier than PhIP-exposed cells. Co-exposure to NB
and PhIP not only accelerated but also significantly increased ROS elevation in cells. It is
recognized that ROS are actively mutagenic and contribute to genomic instability that is
necessary for cellular carcinogenesis [40]. Conversely, NB and PhIP induced similar activation
kinetics of the ERK pathway and combined NB and PhIP resulted in enhanced activation of the
ERK pathway over NB or PhIP alone. ROS elevation and the ERK pathway were mutually
dependent; blockage of one resulted in suppression of the other. Our previous studies suggested
that NB exposure induces ROS elevation leading to ERK pathway activation [7] and that PhIP
induces Ras-ERK-Nox pathway activation resulting in ROS production [9]. Accordingly, coexposure to NB and PhIP induced both ROS to the ERK-Nox pathway and the ERK-Nox
pathway to ROS elevation simultaneously, resulting in reinforced, accelerated and enhanced
ROS elevation. The accelerated and increased ROS levels induced higher levels of DNA
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oxidation and damage in each exposure cycle, contributing to enhanced initiation of cellular
carcinogenesis and leading to enhanced acquisition of cancer-associated properties by cells after
cumulative NBP exposure cycles. Combined NB and PhIP enhanced cellular acquisition of all
the cancer-associated properties we tested, including stem-like and mesenchymal cell properties.
However, whether co-exposure to NB and PhIP may enhance cellular tumorigenicity and
mammary tumor development in animals, as well as human breast cancer development, remains
to be determined.
In our model system, we use transient and constitutive endpoints as targets to validate
preventive agents capable of blocking carcinogenesis initiation and suppressing carcinogenesis
progression, respectively [5-9]. In this communication, we identified two less studied agents,
ergosterol and mimosine, capable of intervening with NBP-induced breast cell carcinogenesis.
Both ergosterol and mimosine, at physiologically-achievable non-cytotoxic levels, were effective
in blocking ROS elevation, Ras-ERK-Nox pathway activation, DNA oxidation, DNA damage,
and cell proliferation induced by a single NBP exposure, which accounted for their ability to
suppress constitutive endpoints induced by cumulative NBP exposures. The combination of
ergosterol and mimosine was more effective than individual agents in blocking transient and
constitutive endpoints. Combined ergosterol and mimosine, used at 5 nmol/L each, was more
effective than individual agents used at 10 nmol/L, indicating that these two agents may act
synergistically in suppression of transient and constitutive properties. It has been suggested that
prevention strategies making use of combined dietary agents are advantageous over those using
individual agents due to higher efficacy and lower toxicity [48]. In addition, considering our
previous [6-9] and current results, combined ergosterol and mimosine appeared to be more
effective and less cytotoxic than green tea catechins for intervention of breast cell carcinogenesis
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induced by NB and PhIP. Thus, ergosterol and mimosine should be seriously considered in
dietary prevention of sporadic breast cancer associated with long-term exposure to multiple
environmental and dietary carcinogens.
Over 85% of breast cancers are sporadic and attributable to long-term exposure to small
quantities of carcinogens [2,3]. Long-term exposure to polluted air, smoke, and diets with hightemperature cooked meats are closely associated with American lifestyles [10,16,20]. In this
communication, we demonstrated that co-exposure to the environmental carcinogens NNK and
B[α]P with the dietary carcinogen PhIP resulted in holistically enhanced initiation and
progression of breast cell carcinogenesis. Using our model as a target, we demonstrated, for the
first time, that a combination of two less recognized dietary constituents, ergosterol and
mimosine, was highly effective in intervention of breast cell carcinogenesis. Notably,
NNK/B[a]P/PhIP-enhanced cellular carcinogenesis and ergosterol/mimosine-mediated
intervention were independent of breast cell type and ER status. Ergosterol is rich in dietary
sources, such as mushrooms, morels, and soy sauce, which are readily available in the United
States [22,23,49]. Mimosine-containing legumes are consumed daily throughout Southeast Asia
and Central America [50]. Thus, dietary components containing ergosterol and mimosine should
be seriously considered in the American diet for affordable prevention of sporadic breast cancer.
However, the roles of long-term human exposure to combined low-dose NNK, B[α]P, and PhIP
in enhanced sporadic breast cancer development and combined use of ergosterol- and mimosinecontaining dietary components in breast cancer intervention will need epidemiological and
clinical studies for validation.
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Figure 3.1. Exposure-dependent enhancement of cancer-associated properties by combined
carcinogens. (A-1 and A-2) MCF10A (10A) cells were repeatedly exposed to combined 100
pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP
(NBP) for 5, 10, 15 and 20 cycles. (B-1 to B-9) MCF10A (10A) cells were repeatedly exposed to
combined NB and PhIP (NBP) for 5, 10, 15 and 20 cycles resulting in the NBP5, NBP10, and
NBP15 and NBP20 cell lines, respectively. MCF10A-Ras (Ras) cells were used as a malignant
control. (A-1) To determine cellular acquisition of reduced dependence on growth factors
(RDGF), cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter
were counted. (A-2) To determine cellular acquisition of anchorage-independent growth (AIG),
cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. (B-1)
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the level
determined in untreated cells, set as 1 (X, arbitrary unit). (B-2) Relative cell proliferation was
determined and normalized by the value of BrdU detected in untreated cells, set as 100%. (B-3)
Total RNA was isolated and analyzed by RT-PCR with specific primers to determine relative
gene expression levels of H-Ras, with β-actin as a control, and these levels were quantified by
densitometry. The levels of H-Ras (Ras/actin) were calculated by normalizing with the level of
β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). (B-4) Cell lysates were
prepared and analyzed by western immunoblotting using specific antibodies to detect levels of
H-Ras, phosphorylated-Raf-1 (p-Raf-1), Raf-1, p-Mek1/2, Mek1/2, p-Erk1/2, Erk1/2, and Nox-1,
with β-actin as a control, and these levels were quantified by densitometry. The levels of H-Ras
(Ras/actin) and Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and
the level set in untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation
of Raf-1 (p/Raf), Mek1/2 (p/Mek) and Erk1/2 (p/Erk) were calculated by normalizing the levels
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of p-Raf-1, p-Mek1/2 and p-Erk1/2 with the levels of Raf-1, Mek1/2 and Erk1/2, respectively,
then the level set in control cells as 1 (X, arbitrary unit). (B-5) To determine cellular acquisition
of serum-independent non-adherent growth (SINAG), cells were seeded in non-adherent cultures
for 10 days. Mammospheres ≥0.1 mm diameter were counted. (B-6) Mammospheres were
collected and trypsinized, and ALDH-expressing (ALDH+) cell population (%) was measured by
flow cytometry. (B-7) Cell lysates were prepared and analyzed by western immunoblotting using
specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin
as a control, and these levels were quantified by densitometry. The levels of EpCAM
(EpCAM/actin), E-cadherin (E-cad/actin), MMP-9 (MMP/actin), and Vimentin (Vim/actin) were
calculated by normalizing with the level of β-actin and the level set in untreated control cells as 1
(X, arbitrary unit). (B-8) Cellular migratory and (B-9) invasive activities were determined by
counting the numbers of cells translocated through a polycarbonate filter without or with coated
Matrigel, respectively, in 10 arbitrary visual fields. Columns, mean of triplicates; bars, SD. All
results are representative of three independent experiments. Statistical significance is indicated
by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 3.2. Enhanced initiation of cellular carcinogenesis by combined carcinogens. (A-1 to
A-5) MCF10A cells were exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB),
10 nmol/L PhIP (P), or combined NB and PhIP (NBP) for 24 h. (B-1 to C-2) MCF10A cells were
exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or
combined NB and PhIP (NBP) for 6, 12, 24 and 48 h. (A-1) DNA damage was measured by a
comet assay and normalized by the value of average tail moment determined in untreated
counterpart cells, set as 1 (X, arbitrary unit). Representative images detected in the comet assay
are shown. (A-2, B-1 and B-2) ROS levels were measured with CM-H2DCF-DA labeling and
normalized by the level determined in untreated cells, set as 1 (X, arbitrary unit). (A-3) Relative
cell proliferation was determined and normalized by the value of BrdU detected in untreated
cells, set as 100%. (A-4) Total RNA was isolated and analyzed by RT-PCR with specific primers
to determine relative gene expression levels of H-Ras, with β-actin as a control, and these levels
were quantified by densitometry. The levels of H-Ras (Ras/actin) were calculated by normalizing
with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). (A-5)
Cell lysates were prepared and analyzed by western immunoblotting using specific antibodies to
detect levels of H-Ras, phosphorylated-Erk1/2 (p-Erk1/2), Erk1/2, and Nox-1, with β-actin as a
control, and these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and
Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the
level set in control cells as 1 (X, arbitrary unit). (C-1 and C-2) Cell lysates were prepared and
analyzed by western immunoblotting using specific antibodies to detect levels of p-Erk1/2 and
Erk1/2 and these levels were quantified by densitometry. The levels of specific phosphorylation
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of Erk1/2 (p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of
Erk1/2, then the level set in control cells as 1 (X, arbitrary unit). Columns, mean of triplicates;
bars, SD. All results are representative of three independent experiments. Statistical significance
is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 3.3. ROS and the Ras-ERK pathway in initiation and maintenance of cellular
carcinogenesis. (A-1 to A-4) MCF10A (10A) cells were exposed to 10 µmol/L U0126 (U) or 5
mmol/L NAC (N) for 24 h; MCF10A cells were exposed to combined 100 pmol/L NNK and 100
pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the absence and
presence of 10 µmol/L U0126 (U0) or 5 mmol/L NAC for 24 h. (B-1 to B-4) MCF10A (10A)
cells were treated with 10 µmol/L U0126 (U) or 5 mmol/L NAC (N) for 10 cycles resulting in
the 10A/U10 and 10A/N10 cell lines; MCF10A cells were exposed to combined 100 pmol/L
NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the
absence and presence of 10 µmol/L U0126 (U) or 5 mmol/L NAC (N) for 10 cycles resulting in
the NB10, NB/U10, NB/N10, P10, P/U10, P/N10, NBP10 NBP/U10 and NBP/N10 cell lines
respectively. (A-1) Cell lysates were prepared and analyzed by western immunoblotting using
specific antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a
control, and these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and
Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the
level set in control cells as 1 (X, arbitrary unit). (A-2) ROS levels were measured with CMH2DCF-DA labeling and normalized by the level determined in untreated cells, set as 1 (X,
arbitrary unit). (A-3) Relative cell proliferation was determined and normalized by the value of
BrdU detected in untreated cells, set as 100%. (A-4) DNA damage was measured by a comet
assay and normalized by the value of average tail moment determined in untreated counterpart
cells, set as 1 (X, arbitrary unit). (B-1) To determine cellular acquisition of reduced dependence
on growth factors (RDGF), cells were maintained in LM medium for 10 days. Cell colonies ≥0.5
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mm diameter were counted. (B-2) To determine cellular acquisition of anchorage-independent
growth (AIG), cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were
counted. (B-3) Cellular migratory and (B-4) invasive activities were determined by counting the
numbers of cells translocated through a polycarbonate filter without or with coated Matrigel,
respectively, in 10 arbitrary visual fields. Columns, mean of triplicates; bars, SD. All results are
representative of three independent experiments. Statistical significance is indicated by * P<0.05,
** P<0.01, and *** P<0.001.
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Figure 3.4. Cytotoxicity of ergosterol and mimosine in MCF10A and MCF12A cell lines.
(A-1 to A-3) MCF10A cells or (B-1 to B-3) MCF12A cells were treated with 100pM, 1nM,
10nM, 100nM, 1µM, 5µM, 20µM and 50µM ergosterol and mimosine individually, or combined
in equal parts. Quantification of cell viability was determined with an MTT Assay Kit, and
relative cell viability was normalized by the value determined in untreated counterpart cells, set
as 100%. Columns, mean of triplicates; bars, SD. All results are representative of three
independent experiments. Statistical significance is indicated by * P<0.05, ** P<0.01, and ***
P<0.001.
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Figure 3.5. Ergosterol and mimosine intervened in cellular carcinogenesis. (A-1 to A-4)
MCF10A cells were exposed to 100 pmol/L NNK, 100 pmol/L B[α]P, and 10 nmol/L PhIP
(NBP) in the absence and presence of 10nM ergosterol (E), 10nM mimosine (M), or combined
ergosterol and mimosine (E+M) at 5nM each for 24 h. (B-1 to C-2) MCF10A cells were exposed
to 100 pmol/L NNK, 100 pmol/L B[α]P, and 10 nmol/L PhIP (NBP) in the absence and presence
of 10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol and mimosine (E+M) at
5nM each for 10 cycles resulting in the NBP10, NBP/E10, NBP/M10 and NBP/E+M10 cell
lines, respectively. (A-1) DNA damage was measured by a comet assay and normalized by the
value of average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary
unit). Representative images detected in the comet assay are shown. (A-2 and B-3) ROS levels
were measured with CM-H2DCF-DA labeling and normalized by the level determined in
untreated cells, set as 1 (X, arbitrary unit). (A-3 and B-4) Relative cell proliferation was
determined and normalized by the value of BrdU detected in untreated cells, set as 100%. (A-4
and B-5) Cell lysates were prepared and analyzed by western immunoblotting using specific
antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a control, and
these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and Nox-1
(Nox/actin) were calculated by normalizing with the level of β-actin and the level set in untreated
control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were
calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the level set in
control cells as 1 (X, arbitrary unit). (B-1) To determine cellular acquisition of reduced
dependence on growth factors (RDGF), cells were maintained in LM medium for 10 days. Cell
colonies ≥0.5 mm diameter were counted. (B-2) To determine cellular acquisition of anchorageindependent growth (AIG), cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm
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diameter were counted. (B-6) To determine cellular acquisition of serum-independent nonadherent growth (SINAG), cells were seeded in non-adherent cultures for 10 days.
Mammospheres ≥0.1 mm diameter were counted. (B-7) Mammospheres were collected and
trypsinized, and ALDH-expressing (ALDH+) cell population (%) was measured by flow
cytometry. (B-8) Cell lysates were prepared and analyzed by western immunoblotting using
specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin
as a control, and these levels were quantified by densitometry. The levels of EpCAM
(EpCAM/actin), E-cadherin (E-cad/actin), MMP-9 (MMP/actin), and Vimentin (Vim/actin) were
calculated by normalizing with the level of β-actin and the level set in untreated control cells as 1
(X, arbitrary unit). (B-9) Cellular migratory and (B-10) invasive activities were determined by
counting the numbers of cells translocated through a polycarbonate filter without or with coated
Matrigel, respectively, in 10 arbitrary visual fields. (C-1) Cellular acquisition of increased
motility was determined by wound healing assay. The wounded areas were examined
(magnification, 100×) 6, 12, and 24 h afterward. Arrows indicate width of wounded areas. (C-2)
To quantitatively measure cell motility detected in F-1, the area not healed by the cells was
subtracted from the total area of the initial wound to calculate the wound healing area (%) at
intervals of 6 (white columns), 12 h (light gray columns) and 24 h (dark gray columns).
Columns, mean of triplicates; bars, SD. All results are representative of three independent
experiments. Statistical significance is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 3.6. Ergosterol and mimosine suppressed oxidative DNA damage induced by
carcinogens. (A-1 and A-2) MCF10A cells were exposed to 100 pmol/L NNK (N), 100 pmol/L
B[α]P (B), combined NNK and B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP
(NBP) for 24 h. (B-1 and B-2) MCF10A cells were exposed to N, B, combined NB, P, or
combined NBP in the absence and presence of 5 mmol/L NAC for 24 h. (C-1 to C-3) MCF10A
cells were exposed to N, B, combined NB, P, or combined NBP in the absence and presence of
10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol and mimosine (E+M) at 5nM
each for 24 h. (A-1 and C-1) DNA damage was measured by a comet assay and normalized by
the value of average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary
unit). Representative images detected in the comet assay are shown. (A-2, B-2 and C-3) DNA
oxidation was measured by an Fpg modified comet assay and reported as the difference in tail
moment between Fpg treated and non-Fpg treated cells and normalized by the value of average
tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (B-1 and C-2)
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the level
determined in untreated cells, set as 1 (X, arbitrary unit). Columns, mean of triplicates; bars, SD.
All results are representative of three independent experiments. Statistical significance is
indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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Figure 3.7. Induction of cellular carcinogenesis in MCF12A cells and suppression by
ergosterol and mimosine. (A-1 to A-4) MCF12A cells (12A) were exposed to combined 100
pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), combined NB and PhIP (NBP)
and NBP in the presence of 10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol
and mimosine (E+M) at 5nM each for 24 h. (B-1 to B-10) MCF12A cells (12A) were repeatedly
exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or
combined NB and PhIP (NBP) for 20 cycles; MCF12A cells (12A) were repeatedly exposed to
combined NB and PhIP (NBP) in the absence and presence of 10nM ergosterol (E), 10nM
mimosine (M), or combined ergosterol and mimosine (E+M) at 5nM each for 10 cycles. (A-1)
DNA damage was measured by a comet assay and normalized by the value of average tail
moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). Representative
images detected in the comet assay are shown. (A-2 and B-3) ROS levels were measured with
CM-H2DCF-DA labeling and normalized by the level determined in untreated cells, set as 1 (X,
arbitrary unit). (A-3 and B-4) Relative cell proliferation was determined and normalized by the
value of BrdU detected in untreated cells, set as 100%. (A-4 and B-5) Cell lysates were prepared
and analyzed by western immunoblotting using specific antibodies to detect levels of H-Ras, pErk1/2, Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by
densitometry. The levels of H-Ras (Ras/actin) and Nox-1 (Nox/actin) were calculated by
normalizing with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary
unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were calculated by normalizing the
levels of p-Erk1/2 with the levels of Erk1/2, then the level set in control cells as 1 (X, arbitrary
unit). (B-1) To determine cellular acquisition of reduced dependence on growth factors (RDGF),
cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted.
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(B-2) To determine cellular acquisition of anchorage-independent growth (AIG), cells were
seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. (B-6) To
determine cellular acquisition of serum-independent non-adherent growth (SINAG), cells were
seeded in non-adherent cultures for 10 days. Mammospheres ≥0.1 mm diameter were counted.
(B-7) Mammospheres were collected and trypsinized, and ALDH-expressing (ALDH+) cell
population (%) was measured by flow cytometry. (B-8) Cell lysates were prepared and analyzed
by western immunoblotting using specific antibodies to detect levels of EpCAM, E-cadherin,
MMP-9 and Vimentin, with β-actin as a control, and these levels were quantified by
densitometry. The levels of EpCAM (EpCAM/actin), E-cadherin (E-cad/actin), MMP-9
(MMP/actin), and Vimentin (Vim/actin) were calculated by normalizing with the level of β-actin
and the level set in untreated control cells as 1 (X, arbitrary unit). (B-9) Cellular migratory and
(B-10) invasive activities were determined by counting the numbers of cells translocated through
a polycarbonate filter without or with coated Matrigel, respectively, in 10 arbitrary visual fields.
Columns, mean of triplicates; bars, SD. All results are representative of three independent
experiments. Statistical significance is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
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General Discussion
The research presented in this dissertation was designed to (1) investigate the ability, and
associated mechanisms, of NB to enhance PhIP-induced chronic breast cell carcinogenesis (2)
evaluate the efficacy of combined dietary agents, such as green tea catechins, ergosterol and
mimosine, in intervention of breast cell carcinogenesis induced by chronic exposure to combined
environmental and dietary carcinogens.

Enhancement of Chronically Induced Breast Cell Carcinogenesis by Combined
Environmental and Dietary Carcinogens
The activity of low doses of multiple carcinogens to induce breast cell carcinogenesis is
an under-investigated area. Since we are all exposed to various carcinogens each day from our
environment and diet, it is important to examine the biochemical and molecular mechanisms and
pathways associated with cellular carcinogenesis induced by each carcinogen and how these
factors interact when carcinogens are combined. Our model system presents several unique
features to advance our understanding of sporadically-occurring human breast carcinogenesis. It
is highly sensitive to detect low physiologically-achievable doses of either weak or potent
carcinogens capable of inducing breast cell carcinogenesis, it exposes cells to carcinogens in a
cumulative manner to mimic progressive induction of chronic carcinogenesis, and it provides
measurable transient and constitutive cellular, biochemical, and molecular endpoints to
determine the induction and progression of cellular carcinogenesis. In contrast, most existing
systems study the activity of carcinogens at high concentrations for acute induction of cellular
carcinogenesis [1-8]. However, since most human cancers result from long-term exposure to low
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doses of carcinogens, a chronic low-dose approach is a more relevant way to study the effects of
environmental carcinogens on human breast cancer development.
Using our cellular model, we demonstrated the ability of the relatively weak mammary
carcinogens NNK and B[α]P (NB) to enhance breast cell carcinogenesis induced by potent
mammary carcinogen PhIP [9]. In addition, we characterized the mechanisms of NB-mediated
enhancement of PhIP-induced cellular carcinogenesis [10]. Our studies revealed that either preor co-exposure to NB significantly enhanced cellular carcinogenesis induced by PhIP, with coexposure being the most potent [9]. MCF10A cells repeatedly exposed to combined NB and
PhIP (NBP) increasingly acquired cancer-associated properties in an exposure-dependent manner
to significantly higher levels than cells exposed to either NB or PhIP alone [9, 10]. Cumulative
exposures to NBP resulted in enhanced acquisition of the cancer-associated properties of reduced
dependence on growth factors and anchorage-independent growth, the stem-like cell properties
of increased mammosphere formation and ALDH-positive cell population and the EMTassociated properties of increased cell migration, invasion and motility [10]. Although induction
of the EMT program and development of stem-like cells have been postulated to play important
roles in cancer development and progression [11], enriched stem-like cell population is not yet
fully appreciated as a breast cancer-associated property. Applying our model system has
advanced our understanding of the involvement of EMT and stem-like cells during breast cell
carcinogenesis and our results suggest that activation of the EMT program and increased stemlike cell population should be considered as novel cancer-associated properties used to measure
the progression of breast cell carcinogenesis.
Mechanistic studies revealed that transient ROS elevation induced by short-term
exposure to NBP played a key role in activating the Ras-ERK-Nox pathway, leading to increased

197

cellular proliferation [10]. Hyperproliferation and elevated ROS levels increased cellular
susceptibility to chromosomal DNA damage and oxidation, which is essential for the induction
of cellular carcinogenesis [11]. Ras-ERK pathway-mediated induction of Nox-1 potentiated ROS
elevation and facilitated the interplay that occurred between the ERK pathway and ROS
production, both of which were required for the initiation and maintenance of NBP-induced
cancer-associated properties. Co-exposure to NB enhanced the capability of PhIP to induce these
transient endpoints during each exposure cycle enabling enhanced initiation of cellular
carcinogenesis and ultimately contributing to enhanced acquisition of cancer-associated, stemlike and mesenchymal cell properties after cumulative exposures. We demonstrated that cellular
exposure to carcinogens can stimulate ROS-mediated Ras-ERK pathway signaling providing
evidence for the involvement of ROS as important signaling modulators during induction and
progression of cellular carcinogenesis induced by chronic carcinogen exposure.

Intervention of Chronic Breast Cell Carcinogenesis by Combined Dietary Agents
Use of combined dietary agents has gained traction in recent years as an effective strategy
for preventing human cancer development. Prevention strategies making use of combined dietary
agents are advantageous over those using individual agents due to higher efficacy and lower
toxicity [12]. Since carcinogenesis occurs in a multi-step process, a variety of agents with
complementary modes of action are needed to effectively suppress this complex disease.
Accordingly, there have been numerous studies that support the use of combined dietary agents
for the prevention of various malignancies including breast cancer [13-21]. In this research, we
used our cellular model as a target system to identify novel combinations of dietary agents
effective in intervention of breast cell carcinogenesis induced by chronic exposure to
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environmental and dietary carcinogens. We employed a two-step strategy which initially used
short-term biological, biochemical and molecular endpoints transiently induced by carcinogen
exposure as targets to identify dietary agents that can block cellular carcinogenesis. The second
step subsequently used long-term cellular acquisition of cancer-associated properties, including
stem-like and mesenchymal cell properties, induced by chronic carcinogen exposure to validate
the ability of preventive dietary agents to suppress cellular carcinogenesis.
Using our cellular model as a target system, we were able to verify the enhanced
preventive activity of combined green tea catechins ECG and EGCG and combined ergosterol
and mimosine, at non-cytotoxic levels, in suppression of NBP-induced chronic cellular
carcinogenesis. In addition, we have identified the mechanisms through which these agents can
counteract the biological, biochemical, and molecular effects of exposure to NNK, B[α]P and
PhIP. We have shown that green tea catechins, ergosterol and mimosine, when used individually
or in combination, are capable of blocking NBP-induced transient ROS elevation, ERK pathway
activation, cell proliferation and chromosomal DNA damage, which accounted for the cytotoxicindependent ability of these agents to suppress cellular acquisition of cancer-associated, stemlike and mesenchymal cell properties. We also revealed the ability of ergosterol and mimosine to
protect chromosomal DNA from oxidative damage caused by carcinogen-induced ROS.
Although ECG was slightly more effective than EGCG, and mimosine was slightly more
effective than ergosterol, a combination of green tea catechins, and of ergosterol and mimosine,
were more effective than individual agents in suppressing induction and progression of NBPinduced breast cell carcinogenesis. Although precise mechanisms still need to be elucidated, it
was evident that the enhanced antioxidant activity of combined green tea catechins and
combined ergosterol and mimosine markedly reduced ROS elevation caused by NBP giving the
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DNA in these cells a level of protection against proliferative and oxidative DNA damage that
neither agent achieved alone. Based on our results, it appears as though a combination of dietary
agents is the best course of action to suppress cellular carcinogenesis caused by exposure to
combined environmental and dietary carcinogens. Therefore, applying our cellular model will
advance our understanding of novel preventive agents that are effective in reducing the health
risk of sporadic breast cancer associated with chronic exposure to carcinogens present in
environmental pollution and American diet.

Conclusion
This study has shown that repeated exposure of non-cancerous, human breast epithelial
MCF10A cells to low doses of the environmental carcinogens NNK and B[α]P enhances various
cancer-associated properties, including reduced dependence on growth factors, anchorage
independent growth, enriched stem-like cell population and activation of the EMT program,
induced by chronic exposure to the dietary carcinogen PhIP. We also detected the ability of
dietary compounds such as green tea catechins, ergosterol and mimosine, at non-cytotoxic
concentrations, to suppress progressive carcinogenesis of breast epithelial cells induced by
chronic exposure to multiple carcinogens. This scheme is summarized in Figure 4.1.
To identify the mechanisms involved in NBP-induced chronic breast cell carcinogenesis,
we characterized biological, biochemical, and molecular changes transiently induced by shortterm carcinogen exposure. Short-term exposure to physiologically-achievable doses of NBP
induced transient ROS elevation leading to ERK pathway activation, cell proliferation, and
chromosomal DNA damage (Figure 4.2A). Ras-ERK pathway-mediated induction of the Nox-1
enzyme facilitated further production of ROS which led to elevated levels of oxidative DNA
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damage. We observed that a combination of the green tea catechins ECG and EGCG, as well as a
combination of the fungal sterol ergosterol and the rare plant amino acid mimosine, were more
effective than individual agents in blocking NBP-induced ROS elevation, ERK pathway
activation, cell proliferation, DNA damage and DNA oxidation, and ultimately suppressing the
progression of cellular carcinogenesis (Figure 4.2B). Our work suggests that use of combined
dietary agents should be seriously considered for early intervention of breast cell carcinogenesis
associated with long-term exposure to multiple environmental and dietary carcinogens.

Future Directions
Co-exposure to NB and PhIP enhanced cellular acquisition of all the cancer-associated
properties we tested; however, whether co-exposure to NB and PhIP may enhance cellular
tumorigenicity and mammary tumor development in animals, as well as human breast cancer
development, remains to be determined. Suppression of cellular acquisition of stem-like celland EMT-associated properties by green tea catechins, ergosterol and mimosine were indicated
by reduction in mammosphere formation, decreased ADLH-positive cell populations and
reversal of EMT marker expression. However, whether or not these dietary agents are able to
protect mammary tissues from acquiring carcinogen-induced stem-like cell and EMT-associated
properties to reduce the risk of invasive tumors remains to be studied.
In our studies, exposure of MCF10A cells to NNK and B[α]P (NB) did not induce any
detectable upregulation of Ras or phosphorylated-Raf, both of which are upstream from Mek1/2
and Erk1/2. Thus, it appears that NB-elevated ROS induced the ERK pathway in a Ras/Rafindependent manner. However, the mechanism for NB-mediated Ras-independent Mek1/2
phosphylation and ERK pathway activation and how ROS was able to induce Ras/Raf-dependent
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and -independent activation of Mek1/2 and Erk1/2 remains to be determined. As a major source
of ROS production, Ras-ERK-dependent expression of Nox-1 plays an important role in redox
signaling and mediates the interplay that occurs between ROS production and the Ras-ERK
pathway in NBP-exposed cells. Cellular exposure to NB did not induce significant expression of
Nox-1 in our studies, presumably because NB did not upregulate Ras expression. However,
whether expression of Nox-1 is reliant on Ras-dependent ERK activation has yet to be clarified.
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APPENDIX
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Figure 4.1
Schematic representation of progressive induction of cancer-associated properties by
chronic exposure to carcinogens and its suppression by dietary compounds
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A)

B)

Figure 4.2
(A) Hypothetical mechanism of NBP-induced cellular carcinogenesis
(B) Hypothetical mechanism of suppression of NBP-induced cellular carcinogenesis
by dietary compounds
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